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Abstract
Aptamers have emerged as potential affinity agents that rival or complement
antibodies in developing diagnostic assays for disease detection. We have demonstrated
the use of PMMA microfluidic devices for conducting rapid affinity microchip CGE of a
target protein using aptamers as the affinity probes with an electrophoresis development
time of <2 min. Migration times were reproducible for thrombin complexes and free
aptamers in CGE buffer with device-to-device RSD variations below 10%. By removing
salts from plasma and adding an unlabeled random sequence oligonucleotide to the
plasma, thrombin was detected in plasma. This method can be easily adapted to highthroughput parallel screening of plasma samples in multi-channel polymeric
microdevices.
The expression of rEpCAM in bacteria and mammalian cells was investigated with
results showing successful expression in the mammalian systems, while protein
expression in the bacteria was inhibited. Higher and prolonged expression levels were
obtained in Cos 7 cells as compared to BHK and Hep2 cells due to episomal expression
in Cos 7 cells. By combining a one-step IMAC procedure with electrophoresis and
electro elution a more selective approach to obtaining electrophoretically pure rEpCAM
was achieved.
We developed dual-aptamer sandwich assays for thrombin and PDGF-BB targets on
PMMA substrate using UV modification with a one-step EDC/NHS coupling reaction.
Results indicate that the use of high EDC concentrations lead to faster immobilization
and increased coverage density with a shorter sandwich assay development time.
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The

assays were sensitive for both proteins and showed linearity in fluorescence response to
changing protein concentration.
Single molecule detection methods provide high sensitivity techniques in which
aptamers can find use. We have demonstrated the use of two aptamers in a FRET-based
assay for the detection of low levels of thrombin. Sensitivity and reliability of the
aptamer smFRET assay depends on complex formation and stability.

Due to the

dissociation constants of the aptamers, single molecule events detected were below the
calculated value for a 6 pM concentration of thrombin. Future work will involve
adjusting the single molecule system by the use of pinholes to enable analysis of higher
sample concentrations.

xv

Chapter 1 Aptamers: A Class of Affinity Compounds with Potential
Applications in Therapeutics and Disease Diagnosis
1.1 Introduction
Affinity agents, such as antibodies, are the central component in many bioanalytical
techniques.

This is due to their high level of specificity and selectivity for the recognition of

targets embedded in complex sample matrices. Antibodies are proteinaceous materials and are
generated in vivo through induction of an immune response in animal hosts or by hybridoma
technology.1, 2 Their use in the development of bioanalytical techniques suffers from certain
disadvantages however, including their protracted method of production, the need for relatively
large targets to induce an immune response in the host, cross reactivity of antibodies with
structurally similar analytes and instability of their tertiary protein structures leading to short
shelf-life. Alternatives to antibodies have been studied which include peptides and nucleic acid
aptamers. The latter group of newly developed affinity agents, aptamers, hold promise as viable
alternatives to antibodies in many bioanalytical methods requiring an affinity agent.1
Aptamer-based molecular recognition applications are rapidly developing into a field that
is projected to be competitive with antibody-based biosensors, immunoassays, and other
analytical formats currently in use.3 Aptamers (derived from the Latin words aptus-to fit and
meros-particle)4 are artificial receptors, primarily DNA or RNA sequences between 15 to 60
bases in length, which are generated in vitro toward target molecules ranging in size from 100
daltons

5, 6

to as large as whole cells.7, 8 They are short single-stranded sequences with specific

and complex three-dimensional structures comprised of stems, loops, bulges, hairpins, triplex or
quadruplex motifs.9 The high affinity displayed by aptamers to a variety of molecules can be
attributed to their ability to incorporate small molecules into their three-dimensional nucleic acid
structure, or to integrate into the structure of larger molecules such as proteins, using
1

noncovalent interactions. These interacts include but are not limited to stacking of aromatic rings,
electrostatic and/or van der Waals interactions, hydrogen bonding, or from a combination of
these effects.10, 11 Aptamers can also adopt an induced-fit mechanism when binding to their
targets in solution. Many aptamers exhibit binding affinities similar to monoclonal antibodies
with dissociation constants (KD) in the nanomolar to micromolar range for small molecules and
B

B

picomolar to nanomolar range for larger targets such as proteins.9
Table 1.1 provides a literature survey of aptamers that have been developed for selected
targets and the dissociation constants. These targets range from as small as divalent metal cations
(zinc and nickel) or organic molecules such as malachite green, ethanolamine and theophylline,
to large targets such as enzymes, antibodies and leukemia cells (see Table 1.1). Also, aptamers
can distinguish between chiral molecules through the design of the aptamers for recognition of a
specific stereoisomer. In a study by Michaud et al (2003) a DNA aptamer capable of recognizing
the D-enantiomer of an oligopeptide, arginine-vasopression, was used as a stationary phase for
liquid chromatographic separation of the L and D stereoisomers of the oligopeptide, in which the
D form was retained by the column while the L form eluted in the void volume.12
Aptamers can be an attractive alternative to antibodies in a variety of research
applications due to their potential as molecular recognition elements with certain advantages
over their antibody counterparts.13

Unlike antibodies, aptamers have the benefits of being

chemically and thermally stable, can be selected toward a wider range of targets (see Table 1.1)
and are generated by in vitro solid phase synthesis techniques without the constraints of in vivo
generation required for antibodies.13
The selection process allows generation of aptamers towards specific regions of the target
whereas the antibody generation process is subject to the immune system of the animal it is
produced in, which means researchers have very little control over the exact epitope an antibody
2

can be raised against.13 Surface immobilized aptamers can be easily regenerated for repeated use
in devices without undergoing denaturation as is observed with antibodies.3 Also, the smaller
size, ease of modification and single stranded structure of nucleic acid aptamers allow their
immobilization on surfaces in a more highly ordered form compared to antibodies, making them
more appropriate for techniques requiring immobilization of affinity agents onto solid support.
The production of aptamers by solid phase synthesis also enables chemical modifications to be
made during production, such as incorporation of functional groups or structural alterations, to
increase stability of the molecule without affecting function.1 The in vitro selection process of
aptamer generation makes it advantageous for quick aptamer selection toward newly discovered
biomarkers even under conditions similar to those used in assays for which the aptamers are
being developed.9, 14
1.2 The Aptamer Generation Process
U

The aptamer selection technique, dubbed Systematic Evolution of Ligands by
Exponential enrichment (SELEX), is an iterative method in which combinatorial elements (i.e.
different sequences of DNA or RNA) are incubated with a target for selection of library elements
that bind tightly to the target.15, 16 The unbound fraction is partitioned off and the bound fraction,
once eluted from the target, amplified by PCR for another round of selection. The process is
repeated until an enriched pool of tightly binding oligonucleotides is obtained. The pool of
oligonucleotides is cloned and analyzed via sequencing to determine the nucleotide content of
the newly generated aptamers (see Figure 1.1). Each step of the SELEX process is of great
importance in order to produce aptamers with very high specificity or low KD values.17
B

B

1.2.1 The SELEX Library
The combinatorial library is usually made up of ribonucleic acids
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or deoxyribonucleic acids

(DNA) and consists of random synthetic sequences of 20 – 80 nucleotides flanked by
3

Table 1.1 Examples of targets used for aptamer selection, the types of aptamers generated and
their dissociation constants.

Targets

Type of
aptamer

Kd

Zn2+

RNA

1.2 mmol/L

Ciesiolka et al. (1995)19

Ni2+

RNA

0.8–29 mmol/L

Hofmann et al. (1997)20

Ethanolamine

DNA

6–19 nmol/L

Mann et al. (2005)6

Theophylline

RNA

100 nmol/L

Jenison et al. (1994)21

Malachite green

RNA

1 mmol/L

Organic dyes

DNA

33–46 mmol/L

Ricin toxin

DNA

58–105 nmol/L

Grate and Wilson (2001)22
Ellington and Szostak
(1992)23
Tang et al. (2006)24

L-tyrosinamide

DNA

45 mmol/L

Vianini et al. (2001) 25

a-Thrombin

DNA

200 nmol/L

Bock et al. (1992)26

RNA

<1–4 nmol/L
164–240
nmol/L

White et al. (2001)27

P

P

P

P

B

B

References

Liu et al. (2003)28

Bovine thrombin

RNA

Immunglobulin E

DNA

23–39 nmol/L

PDGF

DNA

0.1 nmol/L

Mendonsa and Bowser
(2004)29
Green et al. (1996)30

VEGF

RNA

0.1–2 nmol/L

Jellinek et al. (1994)31

TTF1

DNA

3.3–67 nmol/L

Murphy et al. (2003)32

HGF

DNA

19–25 nmol/L

Saito and Tomida (2005)33

L-Selectin

DNA

1.8–5.5 nmol/L

Taq DNA polymerase

DNA

0.04–9 nmol/L

Prion protein (PrPc)

RNA

Hepatitis C virus RdRp

DNA

Tumour marker MUC1
U251 glioblastoma
cells/tenascin-C

DNA

0.1–1.7 nmol/L
1.3/23.5
nmol/L
0.1–34 nmol/L

Hicke et al. (1996)34
Dang and Jayasena
(1996)35
Proske et al. (2002)36

Ferreira et al. (2006)38

RNA

5 nmol/L

Hicke et al. (2001)39

Leukemia cells CCRF-CEM

DNA

0.8–229
nmol/L

Shangguan et al. (2006)40

4

Jones et al. (2006)37

predetermined sequences at the 5’ and 3’ ends for polymerase chain reaction (PCR)
amplification of DNA, transcription or reverse transcription followed by PCR (RT-PCR) when
RNAs are used as the recognition element.9 The complexity of the library depends intimately on
the number of nucleotides in the random region. For example, the theoretical number of unique
sequences for a library containing “n” nucleotides will be 4n, thus a thirty random nucleotide
P

sequence would have 430 (~1.2 x1018) unique sequences.15,
P

P

P

P

P

41

However, most libraries are

generated to contain between 1013 to 1015 individual sequences.13 The oligonucleotide libraries
P

P

P

P

used for aptamer selection can be directly utilized in the SELEX process, with some researchers
preferring to PCR amplify and purify the library prior to the start of SELEX to eliminate
damaged DNA or un-amplifiable sequences that may interfere with the selection process.42 The
use of RNA libraries, however, requires the design of forward primers and oligonucleotide 5’
regions with a T7 promoter sequence for conversion of DNAs to RNAs before the selection step.
Amplification of the bound RNA oligonucleotides occurs by RT-PCR and transcription of the
cDNA back to RNA for subsequent selection steps.9
Important considerations in library design to ensure success in aptamer selection include
the length of the random sequence, which affects the amplification process.43 It has been
observed that long sequences of approximately 80 to 100 bases provide high structural
complexity during the binding process compared to shorter oligonucleotide strands of about 20
to 40 bases, especially for targets not known to bind nucleic acids naturally.3, 9, 42 However, long
oligonucleotide strands with 80 bases or more tend to produce lower yields of full length
products and generate by-products during the PCR amplification process.43 Truncated versions of
the oligonucleotide strands occur as the number of PCR cycles increases above 20 when the PCR
product concentration is increased to between 20- 50 nM and serve as templates from which
single stranded/ double stranded DNA (ss-dsDNA) by-products are produced. Variations in the
5

melting temperatures due to guanine and cytosine compositional differences also cause some
members of the library not to be amplified if the strands are not sufficiently unfolded to allow
primer binding.43

Figure 1.1: In vitro selection of target-specific aptamers using SELEX. The cyclic selection
process uses a synthetic oligonucleotide library made up of either ssDNA or RNA molecules that
are incubated with the target. Following removal of the non-bound fraction of the library, the
bound DNA/RNA sequences are eluted from the target and amplified and this pool subjected to
the appropriate number of cycles. The final pool of oligonucleotides is cloned and sequenced.
Each cycle will produce aptamers with higher specificity and binding strength to the selected
target.
Thus, to circumvent these problems researchers PCR amplify the starting library and purify the
resulting amplicons prior to initiation of the SELEX process.9
6

Because oligonucleotides are composed of only 4 different nucleotide bases, this limits
the possible randomized combinations available in producing these libraries compared to the
alternative synthetic recognition element, peptoids, which are generated from a pool of 20
different amino acids. However, chemical modifications can be introduced into the DNA/RNA
sequences to increase library complexity and also provide conformational stability and/or confer
nuclease resistance characteristics. Typical modifications include replacement of the 2’-hydroxyl
group on the ribose of pyrimidine nucleotides with a primary amine, introduction of a fluoride
or methoxy group to create nuclease resistant RNA (see Figure 1.2).44,45
P

P

Another means of

stabilizing nucleic acid aptamers is to use stereoisomers of the target in the selection process
with subsequent synthesis of the mirror image of the generated aptamer, referred to as
spiegelmers.46 By substituting D-ribose with L-ribose the nuclease resistance of RNA aptamers
can be increased as well.47 Alternatively, the phosphate backbone can be altered by replacing
non-binding oxygen with a sulfur group to increase nuclease resistance.48 Carbon positions 5
and 8 on the pyrimidine and purine bases, respectively, can also be modified with amino acid
groups to generate aptamers capable of tightly binding anionic targets.9 Modified nucleotides,
such as 5-bromouracyl and 5-iodouracil, have been incorporated into aptamer sequences to allow
photo-crosslinking of aptamers to targets.49

With modifications to nucleotide bases, the

complexity of a combinatorial library can be further increased to extend the range of target
diversity to which aptamers can be generated.9
1.2.2 Aptamer Selection Targets
Since its inception in 1990, SELEX has been applied to different classes of targets
ranging from small molecules such as divalent cations,20 ethanolamine,6 and antibiotics50 to large
complex targets such as proteins,26,

29

mixtures of targets (found as aggregates or on cell

surfaces) and whole cells.3, 13, 40 Aptamers can be generated toward targets that are naturally
7

associated with nucleic acids such as nucleotides, cofactors and DNA binding proteins and for
targets not naturally associated with nucleic acids (organic dyes and growth factors).4, 23, 30, 51

Figure 1.2 Possible modifications carried out on nucleotides in generating libraries for SELEX.
Modifications on the ribose sugar create nuclease resistant oligonucleotides while the bases can
be modified depending on the required function. (Adapted from Jayasena, 1999)1
A large percentage of aptamer selections carried out to-date have been directed toward
protein or peptide targets, both free and extra-cellular domain of membrane bound proteins, due
to the large multi-functional surfaces possessed by proteins making them excellent targets for
aptamer selection.26, 34 The wide variety of targets used in aptamer selection gives an indication
of the wide-range applicability of these recognition elements to virtually any target. However, in
order to generate highly specific and tightly binding aptamers for a given target certain

8

requirements need to be met. For example the target should be present at sufficient enough levels
and of very high purity to prevent enrichment of non-specifically interacting oligonucleotides.9
Characteristics that enhance aptamer selection include possession of positively charged
groups (e.g. primary amines), presence of hydrogen bond donors and acceptors and planar
structures (as found in aromatic groups). These allow the aptamers to bind to the target through
a combination of interactive forces such as shape complementarity, aromatic structure and
nucleotide stacking interactions, electrostatic and hydrogen bonding interactions.10, 11, 52

Figure 1.3 The quartet structure formed by guanine molecules in thrombin aptamers: (A) the
quadruplex stabilized by potassium ions and; (B) a diagram depicting the three-dimensional noncanonical structure adopted by the thrombin aptamers when binding to the exosites.
Another interesting feature of aptamers is their ability, in the presence of their targets and
on formation of the binding complex, to undergo adaptive conformational changes. Threedimensional structure formation enables an aptamer to encapsulate small targets while for higher
molecular weight targets different surface sub-structures on the target may be involved in the
aptamer binding process.9, 11 For example, the thrombin aptamers, HD1 and HD22, bind to its
cationic exosites through the formation of a G-quartet structure (see Figure 1.3).
9

Highly anionic or hydrophobic targets are less likely to serve as good targets for aptamer
selection due to molecular repulsion and electrostatic considerations. To minimize these effects,
modifications can be made to the combinatorial library to create cationic or hydrophobic
functional groups in these strands to enhance their affinity toward these targets.

Protein

biomarkers serve as good targets for aptamer selection due to the multifunctional surface groups
that allow oligonucleotides to bind easily. Current advances in protein engineering allow for the
rapid generation of proteins or segments of proteins engineered with fusion tags32 that can be
used as targets for affinity selection processes and biochemical interaction processes. Aptamer
selection against some protein biomarkers are thus carried out with recombinant proteins as
targets. For example, an N-terminus hexahistidine-tagged recombinant of a thyroid transcription
factor was immobilized onto magnetic metal chelating resins and used as a target for SELEX
with the derived aptamer characterized by surface plasmon resonance, enzyme linked assays,
western blot and affinity purification.32
1.2.3 Selection Process
The basic concepts of SELEX developed by Kramer et al.53 were independently utilized
by two groups4, 17 in the early 1990s to develop the general approach for aptamer generation
from a random oligonucleotide library.54 Since then, numerous variations to the original Tuerk
and Gold SELEX method (1990) have been developed. This has given rise to different names
for the SELEX process depending on the factors used for the aptamer selection. For example,
counter-SELEX involves affinity elution of bound aptamers with structural analogs to eliminate
aptamers that bind closely-related compounds.1 Cell-SELEX involves selection of aptamers
against whole-cell targets as was originally done for the generation of the Tenasin C aptamer.55
An example of the cell-SELEX process was recently demonstrated in a study by Shannguan et al
(2006) to generate aptamers for cancer diagnosis. Aptamers were derived toward a lymphoblastic
10

leukemia cell-line (CCRF-CEM) through a counter-SELEX process involving the use of human
Burkitt’s lymphoma cell line (Ramos) as the negative target.40 Figure 1.4 shows the cell-SELEX
process. During the selection process, the unbound fraction of the combinatorial library from the
counter-SELEX process using Ramos cells was used in the selection of high affinity aptamers
toward the CCRF-CEM target. The aptamers were used in flow cytometry studies to determine
their ability to bind specifically to membrane proteins on the surfaces of the leukemia cells.40
Direct interaction of a target with a combinatorial library for a given time period with subsequent
removal of the unbound oligonucleotides forms the selection step of the SELEX process. This
process is application-oriented and does not require in-depth knowledge of the characteristics of
the target. Various methods exist for enhancing the incubation and partitioning of the bound and
unbound fractions of the library during each selection round. These comprise methods that do or
do not require target immobilization.

Target immobilization typically involves column

chromatography in which targets, such as proteins and dye molecules, are immobilized through
affinity interaction or by cross-linking them to support matrices.4,

32

This is the most

conventional method for target immobilization, but requires large amounts of sample to allow
efficient loading onto the columns.56,

57

However, by using magnetic beads and affinity

immobilization, smaller sample sizes can be used and in parallel format for high throughput
screening of different targets in both manual and automated formats, which also enables
elimination of several intermediate steps such as centrifugation and filtration.54
Selection methods requiring no target immobilization include membrane filtration,
capillary electrophoresis (CE-SELEX), Surface Plasmon Resonance, centrifugation, and flow
cytometry.54

Membrane filtration selection utilizes nitrocellulose membranes with various

molecular weight cut-offs to separate unbound oligonucleotides from nucleic acid-target
complexes after pre-incubation of a combinatorial library with the target of interest (usually a
11

protein). After washing to remove unbound oligonucleotides the bound oligonucleotides are
eluted and amplified for the next round of SELEX.

Figure 1.4 A schematic of the cell-SELEX process involving counter-SELEX using negative
control cells to eliminate non-specifically interacting aptamers during the selection process. The
aptamer enrichment steps for the target cells involve utilization of the unbound pool of aptamers
from the counter-SELEX process. (Adapted from Shangguan et al. (2006))40
Another technique demonstrated by Mosing et al, (2005) and Tang et al (2006) is
selection using capillary electrophoresis (CE-SELEX).24,

58

This technique enables faster

generation of aptamers in as few as four rounds. For example, in the studies carried out by Tang
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and co-workers, aptamers were derived against ricin using two in vitro techniques, affinity
chromatography and CE-SELEX. In this study, 10 pM ricin was incubated with the ssDNA pool
for 30 min and separated by CE.

Their results showed that the rate of oligonucleotide

enrichment increased to 60.2% after two rounds of SELEX compared to 38.5% obtained by
conventional SELEX, making CE-SELEX a faster process for aptamer selection against
targets.24 The CE-SELEX method has also been employed in aptamer selection processes for
producing high affinity aptamers against human immunoglobulin E (IgE),29 and HIV reverse
transcriptase.58
1.2.4 Amplification, Elution and Characterization of Aptamers
One major advantage of aptamer selection is the ease of amplification of the bound
oligonucleotides using biosynthetic processes, such as, PCR (DNAs) and RT-PCR (RNAs). In
the enrichment and identification steps associated with SELEX, bound oligonucleotides need to
be amplified due to the complexity of the starting library. Although a high concentration of
starting library can be used, the concentrations of the binding sequences will initially be very low
due to the large number of diverse sequences present, requiring amplification and enrichment in
subsequent processes to increase the amount of high affinity sequences in each round. The
amplification process can be carried out using modified primers to aid in purification and
detection of the aptamers. DNA aptamers only require PCR amplification using Taq polymerase,
while the RNA aptamers require RT-PCR and subsequent transcription.42 Thus, RNA aptamer
SELEX requires the use of primers with a T7 promotor sequence.
For subsequent rounds of selection, the amplified DNA must be in single-stranded form
and unfortunately, PCR generates double-stranded products. As such, techniques must be used to
generate the prerequisite single-stranded form. Reverse primers functionalized with biotin can be
designed to help with immobilization of amplified double stranded DNA (dsDNA) through
13

avidin/biotin interaction with subsequent release of the single stranded DNA (ssDNA) after
denaturing the immobilized dsDNA.32

Other techniques for generating the single stranded

construct include asymmetric PCR in which an excess of one primer is used to generate more of
one type of ssDNA, usually the binding strand.59
Elution strategies for releasing bound aptamers from their targets include heat treatment,
addition of urea, sodium dodecyl sulfate (SDS) or ethylene diamine tetra acetic acid (EDTA) to
disrupt complexation. The use of competitive binders has also been reported in the elution step to
displace a bound target. Selection rounds range between 4 to 20 cycles after which the amplified
sequences are cloned and sequenced to characterize the binding oligonucleotide strands.13 The
number of different aptamers obtained depends on the target and stringency of the selection
process and ranges between 1 and 106. To characterize the aptamers, software programs have
P

P

been developed, such as CLUSTAL W, to help align sequences to determine homology and
mfold for secondary structural conformation determination.9

1.3 Challenges Associated with Aptamers
In spite of the promising research on aptamers and their generation, there are a few
disadvantages associated with them. One of the main disadvantages is that this technology is a
relatively new area compared to antibodies which have been very widely studied, and as such,
not many high affinity aptamers are commercially available.9 Also, not all targets are suitable
for aptamer selection due to the absence of the necessary structural motifs present in the target
that provide molecular interactions for binding to apatmers. For example, anionic and
hydrophobic targets are not suitable for aptamer selection unless modifications are made to the
bases (see Section 1.2.2). Although aptamers can be selected toward a wide range of targets,
research has indicated that aptamers with micromolar to millimolar dissociation constants are
primarily derived for smaller targets (see Table 1.1), which implies lower affinities when
14

compared to antibodies.9 Thus more information is required on the interactions involved in
generation of high affinity aptamers and developing a standard protocol for generating
aptamers.9 For example, in terms of standardizing a protocol for aptamer arrays, Collet et al.
(2005) observed that a single buffer systems could not be used to allow different aptamers to
bind efficiently to corresponding targets.60 Also, modifications to aptamers to confer nuclease
resistance also add to the cost of the aptamers produced.

1.4 Applications of Aptamers
1.4.1 Therapeutic and In Vivo Diagnostic Applications
Aptamers can be adapted to a variety of therapeutic and in vivo diagnostic applications
where affinity agents are required. In the area of therapeutics, aptamers are rapidly catching up
with antibodies.61 The first Food and Drug Administration

62

approved aptamer for therapeutic

function is the vascular endothelial growth factor aptamer which has been approved for treatment
of macular degeneration.61, 63 In the area of in vivo diagnostics, aptamers are in general more
suitable than antibodies for conducting in vivo imaging for disease detection due to the smaller
size of aptamers compared to antibodies, which provides a faster clearance rate in the body for
agents that may be toxic. Aptamers also have lower immunogenicity and can be modified to
extend their half-life in the blood.9
1.4.2 In vitro Diagnostic Applications
In vitro diagnostics (IVD) has been an area of considerable innovation and scientific
advancement over the past decade in an attempt to provide medical professionals with tools to
enable the acquisition of obtain objective information about disease states in order to effectively
and rapidly treat patients.5, 64 Some of the most significant promises come from the utilization of
validated biomarkers to predict a patient’s likelihood of responding to a medicine or avoiding
certain side effects.5 With the yearly growth in the market value of IVD, substantial amounts of
15

resources are being invested into diagnostic research aimed at identifying and validating new
biomarkers and the detection science involved in IVD tests.64, 65
IVD tests can generally be classified as medical tests conducted in a controlled
environment, such as a test tube, outside of a living organism. The FDA’s definition of IVD
products are those reagents, instruments and systems intended for use in diagnosis of disease or
other conditions, including a determination of the state of health, in order to cure, mitigate, treat,
or prevent disease or its sequelae (chronic condition).62,

65

These include analytical and

bioanalytical techniques used in clinical laboratories like mass spectrometry, immunoassays and
electrophoresis;66 and point-of-care (POC) devices, such as biosensors based on several different
transduction modalities such as acoustic, optical and electrochemical detection.64
A new IVD classification category was introduced by the FDA in 1996 as a modification
to its regulatory oversight in the area of IVDs. This category called the analyte-specific reagents
(ASRs) include antibodies, both monoclonal and polyclonal, specific receptor proteins, nucleic
acid sequences and similar reagents which, through specific binding or chemical reaction with
substances in a specimen, are intended for use in a diagnostic application for identification and
quantification of an individual chemical substance or ligand in biological specimens.65 This new
category was based on the recognition by the FDA that ASRs are the active ingredients of inhouse tests, which when used in combination with general purpose reagents and laboratory
instruments, could be the basis for new assays, which could benefit public health.
Antibodies are currently the most widely available agents used in affinity-based
diagnostic techniques that can use biosensors, arrays or bioseparations as the functional platform
for the diagnostic. However, aptamers are rapidly penetrating this area.67 Because of their
robustness compared to antibodies in terms of their ability to withstand extreme pH, temperature
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and regeneration conditions that induce denaturing, they may be more suited for creating
affinity-based assays using the afore mentioned techniques.68
Biosensors are devices that couple a biological recognition element with a physical
transducer to allow for the detection of a target. Commonly used transducers are optical,
electrochemical or mass sensitive devices that generate light, current or frequency signals for
quantitative or semi-quantitative information.13 Using aptamers as recognition elements, several
biosensors have been developed to analyze a variety of targets in real samples. In a study by
Heyduk et al. (2005), a fluorescence-based sensor was developed for the detection of thrombin in
complex matrices using fluorescence resonance energy transfer (FRET) as the readout modality.
Using aptamers that recognized two different epitopes on thrombin, each aptamer was designed
attached via a long linker to a short complementary seven-base sequence to which a donor or
acceptor dye was conjugated (see Figure 1.5).69 In the presence of the target, the aptamers bind
to different epitopes on thrombin causing the dye-labeled complementary oligonucleotide
sequences to anneal generating a FRET response. Other biosensor formats have involved the
interaction of aptamers developed against HIV-Tat and tubulin proteins with transduction
accomplished via surface plasmon resonance, in which thiol functionalized aptamers were
immobilized onto glass slides for capturing the target molecules.70, 71
Microarrays consist of recognition probes covalently immobilized onto a solid support,
such as glass. The recognition elements typically used for microarrays are oligonucleotide probes
for targeting DNAs/RNAs, or antibodies, for targeting proteins. However, aptamers can be used
for microarrays as well. In a study to optimize the conditions for producing aptamer microarrays,
biotin functionalized aptamers were used as capture elements on streptavidin-coated microarray
glass slides.60, 72
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Figure 1. 5 Schematic of the thrombin detecting aptamer beacon designed to produce a FRET
signal when both aptamers bind to thrombin. (Adapted from Heyduk and Heyduk 2005)69
Conditions for effectively generating the microarrays such as pH and buffer composition were
considered. The researchers found that phosphate buffered saline containing 5 mM MgCl2 could
B

B

be used in assays of different targets even though it was not the buffer used in the SELEX
process for some of the aptamers.72 They also demonstrated that aptamer microarrays can be
developed on streptavidin-coated glass slides using automated systems for the detection of
labeled protein in cell lysate.60
In the separation sciences aptamers have been used in affinity chromatography (AC),73
affinity probe capillary electrophoresis (ACE), and capillary electrochromatography (CEC).13 In
AC studies using aptamers in place of antibodies, a biotinylated aptamer of adenosine
immobilized on streptavidin beads was used for the separation of adenosine from its analogues,
cyclic-AMP, NAD+, AMP and ADP. It was observed that the column could selectively retain
and separate ATP and its analogs.74 CEC studies using immobilized thrombin aptamer were
18

carried out to separate non-target analytes such as binary mixtures of amino acids (Dtryptophan/D-tyrosine and D and L-tryptophan) and polycyclic aromatic hydrocarbons.75 Most
separation studies performed using aptamers have been ACE-based to determine the interaction
of aptamers with their targets. The ease of labeling aptamers during synthesis allows generation
of fluorescently-tagged aptamers for detection of analytes of interest or for real-time monitoring
of targets in clinical samples.76 In a competitive assay a fluorescently labeled DNA aptamer was
used for quantifying human immunoglobulin E by ACE.77
The goal of this research was to demonstrate the attributes of aptamers in various
bioanalytical assays using a polymer-based microfluidic format and to evaluate the
immobilization of aptamers for affinity-based methods using polymeric substrates. For example,
in Chapter 2, the use of dye-labeled thrombin aptamers for the detection of thrombin in plasma
by PMMA microchip capillary gel electrophoresis will be discussed. Aptamers have been used
in affinity-based sandwich assays for electrochemical detection in biosensors. In Chapter 4, I will
discuss the application of aptamers in dual-aptamer sandwich assays on PMMA substrate using
fluorescence detection.
Recombinant DNA technology provides a means of producing relatively high amounts of
low abundant biomarkers, such as membrane-bound proteins. This enables the creation of
recombinant proteins in high purity and reasonable amounts that make them appropriate for the
SELEX process to generate aptamers against these targets, which may serve as biomarkers for in
vitro diagnostics. I will also show in this dissertation the cloning and expression of a
hexahistidine tagged recombinant of the epithelial cell adhesion molecule (EpCAM), which is a
membrane protein over-expressed in epithelial cells originating from adenocarcinomas.78 I will
demonstrate in Chapter 3, an extensive technique toward the production of this membrane-bound
recombinant and its purification to greater than 99% purity through the use of immobilized metal
19

affinity chromatography with electro elution. This purified recombinant protein can thus be used
as a target for SELEX to generate aptamers against the native protein, which currently do not
exist (see Table 1.1).
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Chapter 2 Poly(Methyl Methacrylate) Microchip Affinity Capillary
Gel Electrophoresis of Aptamer-Protein Complexes for the Analysis
of Thrombin in Plasma*
2.1 Introduction
Thrombin is a multi-functional serine protease that plays procoagulation and anticoagulation
roles in hemostasis. As a procoagulant, thrombin activates factors V, VII and XI through a
feedback mechanism and converts fibrinogen to fibrin during clot formation. 1, 2 Thrombin also
P

P

regulates coagulation by binding to thrombomodulin to activate protein C.2 Because of its
P

P

importance in the maintenance of hemostatic balance, its level of generation in the blood can be
greatly affected by the onset and progression of certain diseases.
In diseases marked by hypocoagulation, such as hemophilia A and B, which are
characterized by the generation of low levels of factors VIII and IX, respectively,3 clotting time
P

P

is prolonged leading to excessive bleeding due to lower levels of generated thrombin. The role
of thrombin and prothrombin in proteolysis of microtubule associated tau protein in the brain has
been studied as well and hypothesized to be important in the development of alzheimer’s disease
and Parkinsonism dementia of Guam.4 Hypercoagulation in thromboembolic diseases
P

P

P

5-10

, such
P

as acute coronary syndromes in which intracoronary thrombus formation occurs in disrupted
atherosclerotic plaque, is characterized by elevated levels of thrombin.
The aforementioned conditions and the need for tight regulation and reporting on thrombin
levels in plasma creates the need for monitoring thrombin using a simple, robust but highly
sensitive assay.
P

11-13
P

These assays can also be used for determining the effectiveness of

therapeutic treatments, such as administering therapeutic drugs for the treatment of hemophilia 14,
P

15
P

or the use of heparins as anticoagulants after surgery or in thromboembolic disease

treatment.16, 17
P

P

24

Thrombin is responsible for its own non-linear generation, which occurs in two phases. The
first phase results in nanomolar (i.e., 10-30 nM) amounts of thrombin 18 and represents the time
P

P

within which clot formation occurs.2 The second phase, the propagation phase, occurs with 96%
P

P

of thrombin generated and is usually overlooked in some techniques for determining disorders in
hemostasis.

Average thrombin generation profiles reported for normal individuals show

maximum thrombin levels between 200 nM and 800 nM.12, 18
P

P

Current methods available for analyzing thrombin in blood include: Clotting-based assays 19,
P

P

which depend on the time it takes for fibrin formation; monitoring enzymatic activity of
generated thrombin using a synthetic chromogenic
P

20, 21
P

or fluorogenic substrate;

22-24
P

P

immunoassays; 25, 26 or capillary electrophoresis (CE) of hydrolytic products of thrombin’s action
P

P

on fibrinogen. 27 In clotting-based techniques, the time required for clot formation to occur in a
P

P

sample is determined and compared to a clotting standard curve generated using different
concentrations of thrombin. This technique addresses the initiation phase of thrombin generation
since only 10 nM of thrombin is required for clot formation. Although clotting-based techniques
are useful in identifying congenital abnormalities associated with hemophilia A, B and C and for
evaluation of oral anticoagulant therapies, they overlook the propagation phase of thrombin
generation.2,
P

5
P

The propagation phase provides information on the level of depression of

thrombin generation and is most important in hemorrhagic syndromes.
Immunoassays for thrombin include enzyme-linked immunosorbent assays (ELISA) and
western blotting for detecting thrombin-antithrombin III complex, fibrinopeptide A, prothrombin
and factors such as factor V and platelet factor 4.22, 25 These antibody-based assays are typically
P

P

very time consuming requiring assay turn-around-times as long as 24 h or more.
Thrombin assays based on enzymatic activity are very popular approaches for continuously
monitoring the thrombin generation cycle using synthetic chromophore or fluorophore
25

conjugated oligopeptides as performed in the endogenous thrombin potential (EPT) test.15, 20, 24
P

P

This approach can be used in a microtitre plate format for large sample number processing and
also with platelet-rich or poor samples through activation of coagulation by adding human
replicated recombinant tissue factor in the presence of synthetic phospholipids.9, 23 Chromogenic
P

P

assays require the utilization of defibrinated plasma samples in the analysis due to increased
interference from the resulting turbidity when fibrinogen is added to the assay. Fluorogenic
assays are more sensitive and allow for the use of smaller sample sizes compared to their
chromogenic counterparts, however, there is no direct linear correlation between the
fluorescence signal and thrombin activity.28
P

P

Another technique for monitoring thrombin levels is capillary electrophoresis (CE) of
fibrinopeptides with ultraviolet absorption detection.27 CE provides highly efficient separations
P

P

of a wide range of analytes in short development times due to the ability to use high electric field
strengths without degrading separation performance. The capability of this technique to separate
and simultaneously concentrate an analyte in a mixture for identification and quantification
makes CE a valuable technique for the analysis of low levels of potential disease biomarkers.29
P

P

In addition, CE can be used for real-time sample analysis due to its short development times 30.
P

P

Various formats have been developed for CE including affinity capillary electrophoresis (ACE),
which combines high affinity probes, such as antibodies or aptamers, with their respective
binding partners.31,
P

32
P

ACE coupled to laser-induced fluorescence33 detection enables the
P

P

analysis of trace levels of analytes with high specificity.34, 35
P

P

The affinity probe of choice for competitive and non-competitive formats of ACE separations
has traditionally been antibodies due to their high specificity.36 In the competitive format, the
P

P

antigen or antibody is incorporated into the running buffer to maintain complexes formed at
equilibrium. The non-competitive format, also known as non-equilibrium CE, is run without
26

addition of the affinity probe to the CE running buffer such that the equilibrium mixture of
affinity probe and its target are analyzed under non-equilibrium conditions.37, 38 To permit LIF
P

P

detection, the affinity probe can be fluorescently labeled to simplify the implementation of the
assay. Unfortunately, most labeling chemistries for antibody-based affinity probes lead to nonuniformity in the number of dyes attached to the antibody,36 with subsequent generation of
P

P

multiple peaks during electrophoresis and difficulties with quantitation.
The development of aptamers as potential affinity probes can eliminate the problem
associated with multiple labeling due to the ease and uniformity of dye incorporation during
solid phase synthesis of the aptamers.31,

39
P

P

Aptamers are synthetic single-stranded

oligonucleotides, obtained using random nucleotide libraries through Systematic Evolution of
Ligands by Exponential enrichment (SELEX), with high binding specificity for their cognizant
targets.40
P

They are structurally more stable when compared to antibodies,39 making them

P

P

P

attractive alternatives to antibody-based probes for ACE.
Two DNA aptamers, HD1 and HD22, bind with high affinity to thrombin’s exosites I and II,
respectively, and have been used in various applications for thrombin analysis.40,41
P

P

ACE

utilizing aptamers as affinity probes have been carried out using conventional capillary zone
electrophoresis, CZE,42 for studying protein-DNA interactions and in some cases for quantifying
P

P

this target.42, 43 Thrombin and its interaction with anti-thrombin III was studied by ACE with
P

P

real-time monitoring of protein-protein interactions using fluorescently labeled HD1 aptamer.43
P

P

In this study, protein-protein interactions were analyzed using CZE by adding polyethylene
glycol (2%) to the running buffer in order to stabilize the aptamer-thrombin complex. In another
study, Berezovski et al.38 analyzed thrombin-HD1 complexes by non-equilibrium CZE to
P

P

determine binding constants and unknown thrombin concentrations using calculated dissociation
constants and dissociated peak areas from the electropherograms.38
P

27

P

Implementation of various CE formats in microfluidic devices have been proposed for a
number of applications and offers some attractive attributes, such as simplicity in its
implementation, short development times for the electrophoresis, integration of front-end sample
processing steps to the separation platform and potential real-time analysis capabilities. The use
of polymers as the substrate material for microchip CE is particularly attractive due to the
flexibility in the choice of micromanufacturing the devices, the ability to produce chips in a high
production mode and at low-cost and the favorable optical properties of many polymeric material,
such as poly(methyl methacrylate), PMMA.44 In our laboratory, work has been reported on the
P

P

effective utilization of polymeric microchips for many types of bio-separations.45
P

P

In this report, we will discuss the use of microchip electrophoresis using PMMA substrates
for the high resolution and rapid analysis of thrombin in plasma. Microchip CZE and microchip
capillary gel electrophoresis
P

4
P

were evaluated as possible modes to analyze thrombin using

aptamers as affinity probes under non-equilibrium conditions.

Characterization of the

electrophoretic properties of thrombin in the presence of its DNA aptamers, HD1 and HD22, that
were fluorescently labeled were compared to select and optimize the separation best suited for
ACE analysis in terms of separation speed, resolving power and electrophoretic reproducibility.

2.2 Experimental
2.2.1 Reagents and Materials
Human alpha thrombin (MW=37,600 Da), thrombin inhibitor (FPRCK), prothrombin and
human plasma were obtained from Haematologic Technologies Inc. (Essex Junction, VT).
Poly(ethylene glycol), PEG, propionic acid disulfide was obtained from PolyPure (Oslo,
Norway). Alexa Fluor 633 maleimide fluorescent dye was obtained from Invitrogen (Carlsbad,
CA). Immobilized Tris (2-carboxyethyl) phosphine (TCEP) used in disulphide bond reduction
was purchased from Pierce (Rockford, IA).
28

Acrylamide (99%), N, N, N’, N’-tetra-

methylethylenediamine (TEMED) and ammonium persulfate (APS) for linear polyacrylamide
(LPA) preparation and Micro Bio-Spin® 6 chromatography columns were obtained from BioRad
Laboratories (Hercules, CA). Alexa Fluor 647 labeled thrombin specific aptamers, HD1 and
HD22, and unlabeled poly deoxythymidine (poly-dT), (5’Alexa 647 N/sp9/TTT GGT TGG TGT
GGT TGG; 5’Alexa647 N/sp9/TAG TCC GTG GTA GGG CAG GTT GG GG TGA CT; and
TTT TTT TTT TTT TTT TTT), were obtained from Integrated DNA Technologies (Coralville,
IA). Rabbit blood citrate (Colorado Serum Co., Denver, CA) was used as a plasma source.
Methyl hydroxyl ethyl cellulose (MHEC), Tris(hydroxyamino) methane (Tris) and glycine were
from Sigma-Aldrich (St. Louis, MO). Nanopure water was obtained from a Barnstead Ultrapure
water system (Barnstead/Thermolyne, Dubuque, IA) and was used in all buffer preparations and
rinsing steps. PMMA sheets (4 mm thickness for microchip substrate and 0.125 mm thick cover
slips) were obtained from GoodFellow (Berwyn, PA).
2.2.2 Thrombin Labeling Procedure
Human alpha thrombin was site-specifically labeled with Alexa Fluor 633 using peptidyl
chloromethyl ketone inhibitor (FPRCK) as follows: An 87.3 μL aliquot of a 546 μM PEG (n = 7)
acid disulphide was added to 113.7 μL of 100 mM MES (pH 6.0) containing 10 mg/mL 1-ethyl3-[3-dimethylaminopropyl] carbodiimide, EDC, and 12 mg/mL N-hydroxysulfosuccinimide,
NHS, and allowed to react for 15 min at room temperature. The PEG succinimidyl ester
disulfide mixture was reacted with 9.5 μmol of FPRCK for 1.5 h at room temperature. A 30 μL
aliquot of the crosslinker-inhibitor conjugate was treated with immobilized TCEP for 30 min to
reduce the disulphide linkages and 200 μL containing 1 mg of Alexa Fluor 633 maleimide dye
was added. This was allowed to react for 2 h at room temperature with excess ethylene diamine
(0.1 μL) added to terminate the reaction. The dye-labeled inhibitor was filtered by centrifugation
into a solution containing 1 mg of thrombin in HEPES buffer (pH 7.4). This was allowed to
29

react overnight at 4°C with shaking. Alexa Fluor 633-labeled thrombin was purified using
desalting columns and analyzed by denaturing polyacrylamide gel electrophoresis. Labeledthrombin used in the CE experiments was exchanged into the appropriate CE buffer using Micro
Bio-Spin® 6 columns prior to the electrophoresis.
Buffers used for the electrophoresis and aptamer assays contained Tris (25 mM) and Glycine
(19 mM) as the major constituents and adjusted to the required ionic strength and pH. Other
components, such as methyl hydroxy ethylcellulose (MHEC) and LPA were added when needed.
Linear polyacrylamides (LPAs) were synthesized by reacting 800 mg of acrylamide with 38 mg
of APS and 12 μL TEMED in a total volume of 20 mL of Tris-Glycine (TG) buffer. The
reaction mixture was degassed by sonication for 10 min and incubated for 2 h at 60°C. The LPA
produced was precipitated with100% ethanol at 2.5 times its volume, centrifuged and the
precipitate dried and re-suspended in twice its initial volume using a TG buffer.
2.2.3 Optimization of Aptamer Assay Conditions
Binding assays were prepared by incubating unlabeled thrombin with Alexa Fluor 647labeled HD1 or HD22 aptamers in a TG or other CE running buffer. Incubation time was 1 h at
room temperature but later reduced to 10 min when it was observed that binding saturation was
achieved at the shorter incubation time.

Fixed concentrations of aptamer (500 nM) were

incubated with thrombin ranging from 10 nM to 500 nM concentrations for the CE analyses.
2.2.4 Microchip CE
Microchip CE was performed in single channel “simple T” PMMA microfluidic devices with
all separations performed at room temperature. The devices were hot-embossed into 4 mm thick
PMMA wafers using a micro-milled brass mold master.46 All channels were 50 μm wide and 50
P

P

μm deep. A 10 mm injection cross was bisected 5 mm from one end of a 50 mm separation
channel. Holes of 2 mm diameter were drilled at the ends of the channels to provide reservoirs
30

for the separation buffer, sample and waste. A 0.125 mm thick PMMA cover slip was thermally
annealed to each embossed microchip at 107°C for 25 min after cleaning by sonication in
detergent and nanopure water for 6 min followed by drying at 70°C for 30 min. In each series of
experiments, three different PMMA microchips were selected to test assay reproducibility.
All buffers used for the microchip CE studies were filtered and degassed by sonication for 10
min prior to use. Microchip CZE (reverse mode – injection end cathodic and detection end
anodic) of dye-labeled thrombin was performed using a 25 mM TG (pH 8.4) running buffer.
Microchip CGE was accomplished with a TG buffer containing 0.01% MHEC (used to suppress
the EOF and reduce non-specific adsorption) and LPA prepared with 2% acrylamide and
buffered at pH 8.8. The microchips were rinsed for 2 min with 0.2 M NaOH followed by a
nanopure water rinse for the initial use of a microchip device. For microchip CGE, the channel
surfaces were pre-conditioned with 5 mg/mL MHEC in deionized water for 10 min and rinsed
with TG buffer without LPA before filling the device with the CGE running buffer containing
LPA. Microchip CGE was carried out in a reverse mode of operation (injection end cathodic and
detection end anodic).
The electrophoresis equipment used in this work, consisting of four independently controlled
high-voltage power supplies and a laser-induced fluorescence 33 detection system, was assembled
P

P

in-house and has been reported previously.45 Prior to injection, a positive voltage (0.2 kV) was
P

P

applied to the sample reservoir for ~20 s while allowing the other three reservoirs to float.
Sample was then injected by applying a positive voltage (0.3 kV) to the sample waste reservoir
for the required length of time to allow sample to migrate into and fill the fixed volume injector.
Separation was achieved by applying 1.5 kV to the separation waste reservoir (anode) and
maintaining the sample and sample waste reservoirs at 11% and 10% of the applied voltage
applied to the separation waste reservoir, respectively, and grounding the separation buffer
31

reservoir (cathode).

Detection was carried out 2.3 cm from the injection point (effective

separation length, Leff = 2.3 cm) using LIF with an excitation wavelength of 632.8 nm supplied
B

B

by a He-Neon laser. Individual samples of dye-labeled aptamers, HD1 and HD22, were diluted
in the electrophoresis run buffer to a final concentration of 500 nM, while dye-labeled thrombin
was buffer exchanged into TG buffer and diluted to 2 μM with either the microchip CZE or
microchip CGE running buffer.
2.2.5 Standard Curve Generation
A fixed concentration of aptamer (500 nM) was pre-incubated with various concentrations of
thrombin (10 – 500 nM) for 10 min at room temperature in the electrophoresis run buffer and
analyzed by microchip CGE. Electropherogram peak areas for data analysis were integrated
using Microcal Origin software (OriginLab Corp., Northampton, MA). The thrombin/aptamer
complex electrophoretic peak areas were normalized by dividing the complex peak area by the
combined peak areas of free aptamer and complex. These values were used in plotting standard
curves.

The equilibrium complex concentration at each thrombin level was obtained by

multiplying the peak area fractions by the initial aptamer concentrations and plotted against the
initial thrombin concentrations.
2.2.6 Analysis of Plasma Samples
Rabbit plasma was obtained by centrifuging citrated rabbit blood at 2500x for 20 min and
decanting the plasma into clean tubes for storage at -20°C. Human and rabbit plasma, thawed
and centrifuged, were diluted to 10, 25 and 50% in the electrophoresis run buffer and spiked with
dye-labeled HD22 to a final concentration of 500 nM. Each sample was incubated at room
temperature for 10 min with the aptamer solution (500 nM) and analyzed by microchip CGE.
Prior to assay preparation, the plasma was either used without pretreatment or buffer exchanged
into TG buffer containing 0.01% w/v MHEC. Later, unlabeled poly-dT was added to the diluted
32

plasma samples at a 3 μM final concentration to reduce non-specific interactions between dyelabeled HD22 and plasma components.

2.3 Results and Discussion
2.3.1 Optimization of Aptamer Assay Conditions
Various incubation times used for aptamer binding to thrombin in these non-equilibriumbased assays were evaluated and ranged between 10 min to 1 h. Metrics used to optimize the
incubation time included the amount of complex formed and the resolution between the complex
and free aptamer electrophoretic bands. Formation of the G quartet structure is facilitated by the
presence of potassium cations and has been reported to enhance binding of HD1 and HD22
aptamers to thrombin.47-49 Addition of KCl salt up to 5 μM to the electrophoresis buffer resulted
P

P

in a substantial increase in the current level, potentially leading to excessive Joule heating, which
could affect electrophoresis performance in terms of plate numbers. Thus, in this study the
incubation of the aptamers with thrombin was carried out in the absence of K+ ions. The initial
P

P

incubation time of aptamers with thrombin evaluated was 1 h and the electrophoretic peak area
of the complex band was determined. However, it was found that a 10 min incubation time was
adequate to maximize the number of thrombin/aptamer complexes based on the electrophoretic
peak area of the complex. The average complex peak areas obtained for HD22 assays of 50 nM
thrombin incubated at room temperature was 0.19 ± 0.03 for times ranging from 30 min to 1 h,
while the 10 min incubation time gave an average peak area value of 0.20 ± 0.03.
2.3.2 Microchip CZE
Most CE-based affinity assays reported to-date using aptamers as the affinity probe have
employed free-solution capillary electrophoresis. There have been only a few reports in the
literature using affinity capillary gel electrophoresis,
P

50-52
P

which can potentially provide higher

resolution and efficiencies compared to CZE as well as stabilizing the aptamer/thrombin
33

complex when run under non-equilibrium conditions. Thus, in this study we were interested in
comparing the performance of microchip CZE and microchip CGE for the analysis of thrombin
using PMMA microdevices with aptamers as the affinity probes.
To understand the electrophoretic behavior of thrombin using PMMA as the electrophoresis
substrate, dye-labeled thrombin was first analyzed by microchip CZE without the affinity probes.
Figure 2.1a shows a representative electropherogram for the CZE/LIF analysis of dye-labeled
thrombin only. At pH 8.4, the dye-labeled thrombin possessed a migration time of ~5 min (Leff =
B

B

2.5 cm). Subsequent injections on the same device without pre-conditioning the separation
channel resulted in no observable thrombin peak or a very broad peak appearing at ~1,000 s.
The lack of reproducibility between CZE runs was most likely due to alterations in the
electroosmotic flow (EOF) of the PMMA device due to adsorption artifacts. EOF determinations
at pH 8.4 for unmodified PMMA devices and the electrophoretic mobility of the dye-labeled
thrombin indicated that they were very similar in magnitude (see Table 2.1), thus leading to
longer and irreproducible migration times for thrombin during microchip CZE, especially with
slight changes in the magnitude of the EOF due to adsorption to the device wall. In fact, slight
increases in the EOF can cause migration toward the cathode and as such, the thrombin would
not be seen by the LIF detection point, which is located at the anodic end of the separation
channel (reverse mode for electrophoresis).
We also found that attempts to reduce EOF and adsorption by dynamically coat the PMMA
separation channel using MHEC or covalently coating amine terminated polyethylene glycol
through EDC coupling in ultraviolet light activated PMMA channels for CZE did not
dramatically improve the migration time reproducibility for the dye-labeled thrombin (data not
shown). Thus, MHEC coating of microchannel walls was selected as the coating method of
choice.
34

Figure 2. 1: Microchip CE traces of (A) Alexa Fluor 633-labeled thrombin run by microchip
CZE in TG buffer at pH 8.4, E = 300 V/cm, and (B) HD1, HD22 and thrombin (all were labeled
with Alexa Fluor 633) individually analyzed by microchip CGE in TG buffer (pH 8.8) with 2%
LPA and E = 300 V/cm. Peaks appearing before the thrombin peak at less than 40 s in the CGE
electropherogram were due to residual dye from purification of labeled thrombin. The detection
was accomplished using laser induced fluorescence with a He-Neon laser (5 mW of laser power).
For the microchip CGE case, the PMMA walls were conditioned with MHEC prior to the
electrophoretic separation. All separations were performed in PMMA chips.
In order to provide better run-to-run reproducibility for the determination of thrombin, we
investigated the use of microchip CGE since CGE analysis of proteins using low concentration
sieving gels can provide high resolution and high migration time reproducibility.
P

53
P

Thus,

microchip CGE conditions were employed to reduce the detrimental effects of the EOF by
incorporating MHEC to be used as a dynamic coating for the channel walls and LPA added to
the run buffer to serve as a sieving matrix for the affinity complexes and the uncomplexed
components in the sample matrix. For the microchip CGE assays, LPA was prepared and diluted
to about 2% total acrylamide.
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Table 2.1: Microchip CGE and microchip CZE electrophoretic properties of thrombin, its
aptamers and complexes formed in buffer or plasma. Symbols and abbreviations in this Table:
Migration time, asymmetry factor (AF), resolution (Rs) and apparent electrophoretic mobility
(μapp) and electrophoretic mobility (μep). The negative sign on μapp, EOF or μep represents
directional movement from cathode to anode.
B

B

B

B

B

B

B

B

Figure 2.1b shows microchip CGE results of individually analyzed samples of fluorescentlylabeled thrombin and the two dye-labeled aptamers. Addition of LPA to the buffer significantly
enhanced the performance of the electrophoresis leading to highly reproducible migration times
from repeated injections of the same sample loaded into the PMMA devices (RSD <10%, see
Table 2.1). The aptamers exhibited faster migration rates with apparent mobilities (μapp) of 2.67
B

B

x 10-4 and 2.82 x 10-4 cm2 V-1 s-1 for HD1 and HD22, respectively, and higher plate numbers
P

P

P

P

P

P

P

P

P

P

compared to thrombin (see Table 2.1). Thrombin displayed a 10-fold increase in μapp for the
B

B

microchip CGE format compared to microchip CZE due most likely to the diminished EOF
value for the microchip CGE format. Peak asymmetry calculations
P
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for individually analyzed

thrombin and the aptamers showed peak tailing for thrombin and fronting for the
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oligonucleotides, an indication that little interaction between aptamers and the channel walls
occurred while thrombin adsorbed to some extent to the channels even after treatment with
MHEC and addition of LPA to the run buffer.
Μicrochip CGE analysis of pre-incubated mixtures of the dye-labeled aptamers and
unlabeled thrombin resulted in two well-resolved peaks, one for the free aptamer and the other
for the thrombin/aptamer complex. Figure 2.2 shows electropherograms obtained for three
different thrombin concentration (75, 250 and 500 nM) incubated with 500 nM HD1 (A) or
HD22 (B). The resulting electrophoresis profiles differ from the reported traces observed in nonequilibrium CZE of aptamers and their targets, in which only a broad peak of the labeled aptamer
was obtained due to complete dissociation of the complex during the electrophoresis. 38
P

P

The appearance of the complex peak for these non-equilibrium assays is a consequence
of the presence of LPA in the electrophoresis run buffer, which provides a cage effect that can
stabilize the protein/aptamer complexes during electrophoresis promoting re-association when in
close proximity to dissociated aptamers and thrombin.
P
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Also, because of smaller diffusion

constants in gels compared to free-solution,56, 57 dissociation may be greatly retarded during the
P

P

short electrophoresis run times associated with the use of microchip CGE due to locally high
relative concentrations of the ligands and target. The peaks obtained for the microchip CGE
analysis were also reproducible from run-to-run and between devices (see Figure 2.3).
Resolution for the HD22 assay ranged from 3.0 to 1.6 with the resolution dependent upon the
thrombin concentration with higher concentrations producing lower resolution between the
complex peak and the free aptamer. However, the complex peak remained well-resolved from
the free HD22 peak even at the highest thrombin concentration investigated (see Figure 2.2B).
The HD1-thrombin assays showed a similar trend as that of the HD22 assays. Resolution and
plate numbers for both peaks decreased with increasing thrombin concentration. However, as the
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thrombin concentration increased the free HD1 and complex peaks merged (Figure 2.2A)
creating a region of dissociated complex as observed previously. 34
P

P

Figure 2.2: Electrophoresis traces of mixtures of 75, 250 and 500 nM unlabeled thrombin
incubated with Alexa Fluor 647 labeled (A) HD1 and (B) HD22 showing the corresponding
increases in complex peak areas with increasing thrombin concentrations (top to bottom). The
electrophoresis run buffer consisted of TG buffer at pH 8.8 with 2% LPA gel with the microchip
CGE performed using a field strength of 300 V/cm. Electrophoresis conditions were similar to
those described in Figure 2.1B.
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This region between the peaks would complicate peak area calculations for the complex for
generating a standard curve for thrombin. Thus, HD22 was selected for determining the level of
thrombin in real samples due to the fact that the free aptamer and complex peaks were wellresolved irrespective of thrombin concentration. The better resolution for the HD22 assays
compared to HD1 is a direct result of the higher complex thermodynamic stability of the HD22
aptamer to thrombin compared to HD1.
To check the extent of variation in electrophoretic characteristics of aptamers and complex
from run-to-run and device-to-device, three devices molded from the same batch of PMMA were
compared. Migration times were reproducible with variation below 10% RSD from device-todevice and run-to-run (Table 2.1). It was also observed that the level of variation in the
normalized peak area between runs and from device-to-device reduced with increasing thrombin
concentration, especially above 150 nM for the HD22 assays.
2.3.4 Standard Curve Generation
To show the trend in amount of complex produced as the ratio of aptamer-to-thrombin was
varied by increasing the thrombin concentration, normalized complex peak areas were plotted for
different concentrations of unlabeled thrombin used in assays with HD1 and HD22 (see Figure
2.3). No complexes were observed for HD1 assays below 50 nM initial thrombin concentration,
whereas complex peaks could be obtained for the HD22 assay down to 10 nM of thrombin.
Results showed a linear increase in complex peak area formed with increasing thrombin
concentration (see Figure 2.3) up to 150 nM for both the HD1 and HD22 assays (R2 = 0.990).
P

P

The limit of detection, taken as the lowest thrombin concentration for which a complex peak was
produced following electrophoresis, for the HD1 assay was 50 nM while that for HD22 assay
was 10 nM. The difference in detection limits reflects the difference in affinity constants of the
aptamers for thrombin.
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Figure 2.3: Variation of the amount of affinity complex produced with increasing unlabeled
thrombin concentration for assays with HD1 (red circle plot) and HD22 (black square plot), both
labeled with Alexa Fluor 647, in terms of average normalized complex peak areas obtained for
the analyses carried out using three different PMMA microchips. The assays were performed
using PMMA microchip CGE with LIF detection.
HD22 has a lower dissociation constant (KD = 0.5 nM) compared to HD1 with a reported
B

dissociation constant (KD) of 24 nM
B

B
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. Due to the higher stability of the HD22/thrombin
P

complex and its more favorable electrophoretic performance compared to HD1, the remaining
studies used HD22 as the affinity probe.
2.3.5 Analysis of Plasma Samples
Quantitation of analytes in real samples such as blood presents several problems, which
are usually addressed with different sample preparation techniques. Whole blood consists of
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different components with diverse solubility properties that can affect the analytical method of
choice. The ionic strength of blood can increase Joule heating during electrophoresis, while the
presence of cells, carrier proteins such as albumin, and lipoproteins lead to increased protein
adsorption to the separation channel walls. To overcome some of these obstacles, plasma can be
used for these assays. Prothrombin, the inactive form of thrombin, is present in circulating blood.
To evaluate the potential of prothrombin interference in plasma giving rise to false positive
results, 100 nM prothrombin was pre-incubated with HD22 in the electrophoresis run buffer and
was analyzed by microchip CGE. We observed no complex peak using microchip CGE (see
Figure 2.4A) indicating that the affinity probe would not bind to prothrombin. Assay conditions
were optimized using plasma from citrate treated rabbit blood. The plasma samples were tested
at 10, 25 and 50% v/v in the electrophroesis run buffer. After removal of excess salt by
transferring the protein components into TG buffer using Microbio-Spin® 6 columns, microchip
CGE analysis was carried out with LIF detection. Plasma treated only by diluting in the
electrophoresis buffer produced an increase in current above 50 μA even at 10% dilution due to a
higher sample ionic strength. After exchanging the plasma into TG buffer, the main problem
faced was adsorption of protein to the channel walls and association of the labeled aptamer with
carrier proteins in the sample. This caused an increase in background fluorescence resulting in no
electrophoretic peak for the thrombin/HD22 complex.
Studies carried out on aptamers have reported the use of excess non-specific
oligonucleotides as competitors to enhance aptamer selectivity.
P
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This technique was thus

employed in an attempt to minimized non-specific interaction between plasma components and
HD22. Unlabeled poly-dT at 3 μM was added to the plasma prior to adding the HD22 reagent.
This allowed formation of a free aptamer peak and a complex peak during electrophoresis (see
Figures 2.4B, C and D). The plasma samples were again tested at 10, 25 and 50% levels. The
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10% plasma dilution enabled repeated injections of the same sample load while 25% plasma
dilution could only be injected once after which the microchip had to be thoroughly cleaned due
to highly irreproducible electrophoretic results. Electropherograms could not be generated for a
50% plasma sample due to increased current and poor peak shape and in some cases, the absence
of the target complex peak. A slight shift in the migration time of the HD22/thrombin complex
occurred for the plasma samples compared to the control samples most likely due to interaction
of thrombin with components of hemolized blood.

Figure 2. 4: Representative microchip CGE traces for HD22 assays in TG buffer (pH 8.8 E =
300V/ cm) for (A) 100 nM prothrombin analysis in buffer and (B) 25% rabbit plasma, (C) 10%
and (D) 25% human plasma samples. Plasma samples were desalted and buffer exchanged into
CGE buffer without LPA prior to dilution and microchip CGE analysis.
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Based on the results obtained from rabbit plasma, human plasma was also analyzed for the
presence of thrombin using affinity microchip CGE and the HD22 aptamer affinity probe. Ten
and 25% dilutions of buffer exchanged plasma were analyzed with 500 nM HD22 (see Figures
4C and 4D).

Microchip CGE results indicated the presence of thrombin at an average

concentration of 543 ± 81.5 nM (see Table 2.1). This falls within the generated thrombin
concentration range found in the literature.
P

12
P

The time required for sample preparation and

analysis by this microchip CGE technique was relatively short (approximately 14 min for sample
preparation and 2 min for microchip CGE).

2.4 Conclusion
We have demonstrated the use of PMMA microfluidic devices for conducting rapid affinity
microchip CGE of a target protein using aptamers as the affinity probes with an electrophoresis
development time of <2 min. For these microchip CGE assays, non-equilibrium conditions were
used to allow for the sensitive LIF detection of thrombin without requiring fluorescence labeling
of the target. Migration times were reproducible for thrombin complexes and free aptamers in
CGE buffer with device-to-device RSD variations below 10%. By removing salts from plasma
and adding an unlabeled random sequence oligonucleotide to the plasma, thrombin was detected
in rabbit and human plasma. This method can be easily adapted for high throughput screening of
plasma samples in a polymeric microchip device designed with multiple channels for analyzing
several samples in parallel. Work is currently underway in our lab to develop detection systems
for use with high throughput polymeric microchips for use with assays requiring high throughput
screening capabilities.
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Chapter 3. Investigating the Expression of Recombinant EpCAM in
Bacteria and Mammalian Cells and the Development of a Selective
Tandem IMAC/ Electro Elution Purification Protocol for HistidineTagged Recombinant Proteins in Mammalian Cells
3.1 Introduction
Affinity-based bioanalytical techniques play a pivotal role in disease diagnosis and
prognosis due to the high target specificity and selectivity afforded by the affinity agents used in
these methods. Forty percent of eukaryotic cell proteins, which often times are used as
biomarkers in diagnostic assays, are membrane-bound. These proteins can also serve as effective
targets for drug development and antibody generation in disease treatment and diagnosis.1
However, the need exists for obtaining the target proteins in a highly abundant and purified form
in their native states to ensure recognition of the native target in complex environments by the
affinity agent when used for affinity probe selection or designing and testing the biomolecular
assay.
In many affinity-based techniques, the common and commercially available molecular
recognition element used has been antibodies either monoclonal or polyclonal.2

Recently,

alternative recognition probes are becoming popular, such as aptamers or peptoids due to their
ease of synthetic production, favorable chemical stabilities and good biochemical
compatibilities.3-5 Unfortunately, few aptamer/peptoid probes are available for the large number
of molecular/cellular targets used in many diagnostic assays.6 Therefore, to expand the library of
aptamer/peptoid probes available for molecular recognition, large amounts of high purified target
surrogates will be required for probe selection.
Recombinant DNA technology (RDT) allows for the production of protein targets through
manipulation of the complementary deoxyribonucleic acid (cDNA) generated from the proteins
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of interest through, for example, incorporation of fusion tags to meet protein production and
purification requirements of researchers.7, 8
Recombinant protein expression consists of three components: a gene of interest, a vector
for gene transfer into the appropriate host and the host for protein expression.9 Figure 3.1 shows
a schematic of the cloning and expression process.

Figure 3.1 A schematic of the molecular cloning process. RNA extracted from an overexpressing source of the protein biomarker is reverse transcribed to the cDNA of the target.
After PCR amplification the cDNA insert is enzymatically incorporated into the vector with
subsequent transformation of bateria with the recombinant vector. The recombinant vector
containing the gene of interest is amplified by culturing the transformed bacteria in the presence
of antibiotic and purified for transfection of eukaryotic hosts or transformation of bacteria for
protein expression.
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Starting with RNA extracted from a source that over-expresses the protein of interest, reversetranscription is performed to obtain the cDNA. The cDNA thus obtained is amplified by
polymerase chain reaction (PCR) and ligated into a vector, such as a plasmid. The recombinant
plasmid is amplified in bacteria by inducing uptake of the plasmid by the bacteria strain of
choice, a process referred to as transformation. The transformed bacteria is cultured in the
presence of an antibiotic to which a resistance gene exists in the vector to enable selective
growth of only bacterial cells containing the recombinant plasmid. The amplified plasmid is
purified and used in the transfection of eukaryotic hosts or bacteria transformation for protein
expression (see Figure 3.1).10
A wide variety of vectors are available for rapid and high throughput cloning of protein
biomarkers in prokaryotic, eukaryotic and cell-free systems.11

Integral membrane proteins

(IMPs) are physiologically responsible for interfacing extracellular biochemical activities with
intracellular ones.12 They are implicated in various diseases and thus, approximately 50% of all
drug targets are G-protein coupled receptors.

12-14

However, a major setback to structural

determination studies on eukaryotic IMPs is the expression and purification of sufficient amounts
of homogeneous protein. The complexity of eukaryotic IMPs presents problems with their
expression in prokaryotic systems.14 Thus, most eukaryotic IMP recombinants are expressed in
eukaryotes, such as insect and mammalian hosts in spite of the lower yields.13 Currently,
approximately 60-70% of all recombinant protein pharmaceuticals are produced in mammalian
cells, the most commonly used being the Chinese hamster ovary cells, due to the possession of
organelles that allow post translational modification of proteins to generate them in their native
conformations.7, 15, 16
An important aspect of recombinant protein production requiring detailed planning to
ensure very high levels of yield and purity while maintaining the protein’s structural properties is
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the purification process.

To this end affinity purification techniques involving the use of

antibodies or other affinity agents play a very important role in recombinant protein production.
A widely used affinity method is the immobilized metal affinity chromatographic (IMAC)
technique for purification of histidine tagged recombinant proteins from cell lysates and growth
media either in conjunction with other purification methods or as a one-step procedure with
protein yields >95%.17-21
Unfortunately, eukaryotic cells have higher contents of cysteine and histidine compared to
prokaryotes which bind to metal ions when exposed in clusters on protein surfaces under native
conditions.22, 23 This leads to interference with IMAC purification of recombinant proteins from
the expression hosts. Thus, to ensure high levels of protein purity, the IMAC technique can be
used in conjunction with other purification techniques to remove co-eluting impurities.
Electrophoresis has become an invaluable tool for protein analysis and purification.24

An

electrophoretic method commonly employed as an extraction technique for isolating protein
bands from electrophoresis gels is electro elution. This purification and extraction method
enables researchers to obtain highly purified biomolecules, such as proteins, in native form with
yields ranging between 80 - 100%.24 Electro elution, carried out either in static or continuous
mode, has proven useful in the recovery of recombinant proteins from cell lysates. The technique
has been employed in the continuous format for single-step purification of recombinant proteins
from bacterial expression systems and inclusion bodies.25-27 Electro elution has also been used as
a second purification step in, for example, the purification of tristetraprolin from an enzyme
digest of an affinity purified recombinant fusion protein.28
By coupling affinity chromatography with electro elution, electrophoretically pure
histidine-tagged recombinant proteins expressed in eukaryotic systems may be obtained in native
conformation for further downstream processes.29
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The technique is also adaptable to

microfluidic systems for simultaneous and high throughput processing of several protein
biomarkers due to the ease of miniaturization of electrophoretic processes and chemical
modification of polymeric substrates for immobilization purposes.1
To study the cloning and expression characteristics in various expression systems and to
develop a purification protocol for laboratory-scale production of integral membrane proteins,
we chose the epithelial cell adhesion molecule (EpCAM), a 40 kilodalton transmembrane protein
over expressed in breast cancer and other carcinomas, as our model.30, 31 In this study we cloned
EpCAM as a hexahistidine-tagged fusion protein in two different vectors for expression in
mammalian and bacterial cells to optimize its expression for purification. A purification protocol
based on tandem IMAC with electrophoresis and electro elution to obtain a pure and correctly
folded protein as determined by western blot and sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE) was developed.

3.2 Experimental
3.2.1 Cell Lines
Breast carcinoma cell lines MCF7 (HTB), Hs578T used for total RNA extraction and
western blots of EpCAM, baby hamster kidney (BHK) cell line, cervical cancer cell line (Hep2),
and Cos 7 cell line used in cloning and expression of recombinant EpCAM were obtained from
the American Type Culture Collection (Manassas, VA). Cells were stored in liquid nitrogen and
at – 80 °C until required.
3.2.2 Reagents and Materials
Cloning reagents and kits include Novagen UltraMobius plasmid kits (EMD Bioscience,
San Diego, CA), Qiagen RNA/DNA mini kit (Hilden, Germany), lipofectamine and mammalian
expression vectors obtained from Invitrogen Corp.(Carlbad, CA) were pEF6/V5-His TOPO TA®
P

and pcDNA 3.1 (+). EpCAM specific primers (Forward: 5’-AGC ATG GCT CCC CCG CAG
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P

GTC C-3’ (bases 176-197); Reverse : 5’- GGC GTT GAG TTC CCT ATG CAT CTC AC CAT3’ (bases 1091-1116)) flanking the region including the signaling peptide through part of the
cytoplasmic region used for polymerase chain reaction (PCR) amplification of EpCAM cDNA
were synthesized by Integrated DNA Technologies (Coralville, IA) based on the messenger
RNA sequence of the tumor associated calcium signal transducer (TACSTD1: NM_002354)
obtained from the National Center for Biotechnology Information (NCBI) website. Restriction
endonucleases and Quick Ligation kit used in the cloning process were obtained from New
England Biolabs Inc. (Ipswich, MA). Criterion Tris-HCl gels and electrophoresis and western
blotting buffers were obtained from BioRad Laboratories (Hercules, CA).
Talon® metal affinity resin used in affinity purification of recombinant EpCAM was
P

P

obtained from ClonTech Laboratories Inc. (Mountain View, CA). FluoStar Optima microtiter
plate reader (BMG LabTech, Durham, NC) was used for total protein determination by
Biccinchonninic assay (BCA) (Pierce, Rockford, IL) and DNA quantitation by Cyquant cell
proliferation assay (Invitrogen, Carlbad, CA). Western blot reagents and antibodies utilized
included Full Range Rainbow Protein marker, ECL Plus western blotting reagent (GE Healthcare,
Piscataway, NJ), MagicMark XP western protein marker, anti-V5 , C-terminus anti-Histidine
monoclonal (Invitrogen, Carlbad, CA), anti-hEpCAM (R&D, Systems, Minneapolis, MN) and
anti-EpCAM VU D9 clone (EMD Biosciences, Inc., La Jolla, CA) primary antibodies.
Detergents used in cell solubilization studies include dodecyl-β-D-maltoside (DDM) and sodium
deoxycholate (DOC) from Sigma-Aldrich (St. Louis,MO), nonidet P40 (NP40) and n-octyl-β-Dglucopyranoside (OβDG) from EMD Biosciences (La Jolla, CA). Sodium molybdate used in
NP40 buffer preparations and imidazole used in the purification studies were obtained from
Sigma-Aldrich (St. Louis, MO).
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3.2.3 Production of EpCAM cDNA from Total RNA of Breast Cancer Cells and Generation of
EpCAM/Vector Constructs
MCF7 and Hs578T breast cancer cells were cultured in Dubelco minimum essential
medium (DMEM)

in p60 culture dished under 6% CO2 at 37°C until the cells reached
B

B

approximately 90% confluency. The adhered cells were first washed with sterile phosphate
buffered saline (PBS) and solubilized with 1% SDS solution. After shearing the DNA and
centrifuging to remove debris, the total protein contents of the lysates were determined by
bicinconninic acid assay (BCA). Aliquots of lysate containing 50 ug of total protein were
analyzed by western blot to determine which cell line produced the highest level of EpCAM.
MCF7 cells were cultured to 90% confluence and the cells harvested for total RNA extraction
following the instructions for the Qiagen RNA/DNA kit. Total RNA was reverse transcribed
using poly-dT primers to provide cDNA from which EpCAM cDNA was PCR amplified with
EpCAM specific primers for cloning. The PCR amplification temperature cycle involved a 3 min
initial denaturation at 95 °C followed by a 25 round thermal cycle of 30 s at 95 °C, 1 min at
58 °C and 1 min at 72 °C. A final extension at 72 °C for 7 min was carried out prior to cooling
the PCR reaction to 4 °C.
To generate histidine tagged EpCAM cDNA containing vectors for transformation and
transfection, EpCAM cDNA obtained from RNA of MCF7 cells was first cloned into the
pEF6/V5-His TOPO TA® mammalian expression vector for bacteria transformation as follows;
P

P

PCR amplified EpCAM cDNA was added to the TOPO vector without prior purification and
allowed to incubate for 5 min at room temperature. Competent E coli cells were transformed
with the recombinant TOPO/EpCAM plasmid and cultured on Luria broth (LB) agar with 50
ug/mL ampicillin overnight at 37 °C following the TOPO kit protocol. The transformed E. coli
cells were tested for the presence of EpCAM cDNA by PCR of heat lysed cells using EpCAMspecific primers. Colonies which tested positive for EpCAM cDNA were cultured in Luria broth
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(LB) containing 50 μg/mL ampicillin at 37 °C for 16 h. Purified recombinant plasmid was
obtained using the UltraMobius plasmid extraction kit and analyzed by restriction enzyme digest
to determine the correct insertion of EpCAM cDNA into the vector based on the DNA fragment
sizes obtained. Large scale plasmid preparation was carried out to obtain purified recombinant
TOPO plasmid for extraction of EpCAM-V5-His6 DNA sequence.
B

B

Transfer of EpCAM-V5-His6 cDNA from the TOPO/EpCAM plasmid to pcDNA 3.1 (+)
B

B

vector was achieved by digestion of the TOPO/EpCAM plasmid with Kpn1 and EcoRV
restriction endonucleases and digestion of pcDNA 3.1 (+) with Kpn1 and Pme1 enzymes. The
digested insert and vector DNA were agarose gel purified and extracted using the Novagen
UltraMobius mini plasmid prep kit. The insert and plasmid DNA were then quantified and
combined in a molar ratio of 3:1 insert to plasmid. Using the Quick ligase kit, a 5 min ligation of
the EpCAM-V5-His6 insert into pcDNA 3.1 (+) was carried out to generate the pcDNA/EpCAMB

B

V5-His6 recombinant plasmid. Transformed bacteria colonies containing this plasmid were
B

B

selected on LB ampicillin (LB-amp) agar and determined to contain EpCAM cDNA by PCR.
The transformed bacteria were cultured for plasmid preparation and storage at -80 °C in 10%
glycerol. Recombinant plasmid for bacterial expression of recombinant EpCAM (rEpCAM) was
prepared by digestion of pTriEX-4 Neo vector with Xho 1 and Eco RV and sequential digestion
of pcDNA/EpCAM-V5-His6 with Xho 1 followed by Pme 1. The purified cut vector and insert
B

B

were ligated as previously described and transformed in bacteria for amplification.
All three recombinant plasmids were analyzed by restriction enzyme digest to determine
the orientation of the insert in the vector. Fragments obtained were separated on 1% agarose and
the sizes compared to the calculated fragment sizes. TOPO/EpCAM and pcDNA/EpCAM-V5His6 were sequenced using EpCAM, T7 and BGH primers to verify correct sequence orientation
B

B

and the absence of mutations in the EpCAM cDNA.
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3.2.4 Bacteria Expression of rEpCAM
pTriEx-4/EpCAM transformed Tuner (DE3) pLacI cells cultured in LB medium
containing75 μg/ mL carbenicillin, 34 μg/ mL chloramphenicol and 1% glucose overnight at
37 °C served as a starter culture for seeding fresh medium. The cells were allowed to grow for 3
h to an optical density (OD) between 0.5 and 1.0, measured at 600nm wavelength. Protein
expression was induced with different IPTG concentrations ranging from 0 to 1 mM and the
cultures incubated for 2.5 h. Aliquots of 1.5 mL cell suspension were centrifuges at 12, 0000 x g
for 5 min and the cell pellets washed three times with phosphate buffered saline (PBS) before
being lysed in reducing Laemli buffer and heat denatured for electrophoresis and western blot
analysis. OD measurements were obtained at various time intervals for EpCAM transformed
tuner cells and control tuner cells cultured without IPTG to determine the growth pattern of the
cells and for cultures before and after IPTG induction.
3.2.5 Expression of C-Terminus Histidine-Tagged Recombinant EpCAM in Mammalian Cells
Three mammalian cell lines BHK, Hep 2 and Cos 7 were transfected with
pcDNA/EpCAM for mammalian expression of rEpCAM. The cells were grown to approximately
90 % confluence, rinsed with PBS to remove growth medium and treated for 30 min with a
suspension of lipofectamine emulsified recombinant vector in growth medium. The transfected
cells were cultured in the presence of 400ug/ mL G418 selection agent over a two week time
period to create a rEpCAM expressing stable cell line. Cells were harvested every five days after
transfection to test for the presence of rEpCAM by western blot using anti-EpCAM, antihistidine or anti-V5 primary antibodies.
3.2.6 Purification of Recombinant EpCAM
EpCAM expressing BHK cells were used in determining the best detergent for cell
solubilization. Mild detergents DDM, DOC, NP40 and OβDG were selected and compared to
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SDS to obtain the most effective non-denaturing detergent in terms of protein content. Cells in
p10 plates were cultured under antibiotic selection until 90% confluency at 37 °C. The cells were
rinsed with cold sterile tris buffered saline (TBS) and treated with 500 μL each of TBS
containing different detergents and protease inhibitor cocktail. The cells were scraped and
solubilized by several passes through 25 gauge syringes. The crude lysates were centrifuged for
10 min at maximum speed in a microcentrifuge to separate insoluble cell debris from the
supernatant. Cell pellets were solubilized in 1% SDS in TBS and total protein contents of both
fractions were determined spectrophotometrical using the BCA method for total protein. Lysate
aliquots containing 50 μg total protein, were loaded on Criterion 10% tris-HCl gels and
electrophoresed at 100 V for 2.5 h.

The resolved proteins were electro-transferred to

nitrocellulose membrane at 100 V for 60 min in tris-glycine buffer for western blot analysis.
Nonidet P40 detergent was selected for cell solubilization and added to Tris saline buffer at
0.09% with 10 mM sodium molobdate.
3.2.7 Optimization of mMetal Affinity Purification Protocol for Recombinant EpCAM
Clarified cell lysate containing the recombinant protein was incubated with Talon® resin
at a ratio of 1:5 resin-to-lysate volume for 2 h at room temperature or overnight at 4 °C on a
shaker. Subsequent incubations were performed overnight at 4 °C, since this condition allowed
maximum binding of protein to the resin. Bound protein was then washed with 10 column
volumes of buffer containing different imidazole concentrations ranging from 1 mM to 50 mM to
determine the most appropriate imidazole levels which would allow removal of non-specifically
bound proteins while retaining the bulk of the recombinant protein on the resin. Other additives
such as 5% glycerol, sodium chloride (500 mM) and beta mercapto-ethanol (BME) (10 mM)
were introduced in the binding and washing stages for protein stability and to determine their
effectiveness in reducing the level of non-specifically bound proteins. Each wash step was
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carried out in triplicate with 3 min room temperature incubation periods on a shaker and the
buffer removed by centrifugation for 2 min. The purified recombinant protein was eluted from
the resin with one column volume of buffer containing imidazole at concentrations between 75500 mM or EDTA (100 mM) and the eluted resin treated with 1% SDS solution to check the
effectiveness of the elution buffer during the purification optimization process. Imidazole at 500
mM concentration was selected for elution of bound protein during the scale-up process. IMAC
fractions were analyzed by SDS PAGE and western blot to ascertain which fractions contained
the recombinant EpCAM and the level of its purity. Fractions collected were loaded on 10%
polyacrylamide gel in volumetric ratios to allow comparison of the rEpCAM levels in each
fraction.
3.2.8 Gel Electrophoresis and Western Blot Analysis
Samples of lysate and purification fractions were loaded on 10% polyacrilmide gels and
electrophoresed at 100V for 2.5 h.

The separated proteins were electro-transferred to

nitrocellulose membrane (BioRad laboratories, Hercules, CA) after which the membrane was
washed and blocked for 1 h with 5% skim milk in PBS buffer containing 0.05% Tween 20
(PBS-T). The membrane was incubated overnight at 4°C with anti-EpCAM antibody in 5%
skim milk in PBS-T, washed 3 times with PBS-T for 5 min each and incubated 1 h at room
temperature with horse radish peroxidase (HRP) linked secondary antibody. The membrane was
washed 3 times with PBS-T and ECL Plus western blotting chemiluminescence detection reagent
added for 5 min. Presence of rEpCAM was determined by exposure of the membrane to
photographic film.
3.2.9 Electro Elution of rEpCAM from SDS-PAGE Gels
Pre-concentration of IMAC purified protein eluates was carried out by centrifugal
ultrafiltration using centricon devices with molecular weight cut-offs (MWC) of 50, 30 and 10
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kilodaltons (kD) and, in later experiments, by dialysis using MWC 20 kD slide-a-lyzer cassettes
and concentrating solution. The rEpCAM concentrates were electrophoresed on 10 % Criterion
Tris-HCl gels to separate the target protein from co-eluting proteins. The gels were stained with
E-Zinc reversible stain (Pierce, Rockford, IL) and the rEpCAM bands excised and destained with
tris/glycine buffer. The protein was electro eluted from the gel in a Model 422 Electro Eluter
(BioRad Laboratories, Hercules, California) for 5 h in tris/glycine buffer with 0.05% SDS. The
extracted protein was removed and concentrated by centrifugal ultrafiltration and analyzed by
SDS-PAGE and western blotting.

3.3 Results and Discussion
In this study, two breast cancer cell lines (MCF 7 and Hs578T) were selected as sources
for EpCAM due to over-expression of this biomarker in these cell types. The cells were cultured
and the total protein content determined followed by western blot analysis to determine the
relative EpCAM expression level in each cell type. Results showed a higher level of the target
protein generated in the MCF 7 cells compared to the Hs578T cell line due to a faster growth rate.
Thus the MCF 7 cell line was our source for total RNA extraction for the cloning process. Total
RNA was converted to cDNA from which the EpCAM cDNA was obtained for further cloning
steps.
3.3.1 Insertion of RT-PCR Amplified EpCAM cDNA into the Vectors
PCR amplification of EpCAM cDNA carried out with primers flanking regions of the
EpCAM cDNA from bases 176 to 1116 yielded a sequence greater than 900 bp in size on 1%
agarose gel, which corresponds to the expected 941 bp cDNA size calculated using the EpCAM
mRNA sequence (Locus: NM_002354) obtained from the NCBI website. This portion of the
EpCAm sequence encompasses the regions of the protein starting from the signaling peptide
through most of the cytoplasmic domain. The amplified sequence was immediately inserted into
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the pEF6/V5-His TOPO plasmid without the need for prior purification of the pcr product.
Results of cloning and sub-cloning EpCAM cDNA into TOPO, pcDNA 3.1 (+) and pTriEx-4
Neo vectors are shown in figure 3.2. Recombinant plasmids generated for EpCAM expression
were restriction enzyme digested and analyzed by agarose gel electrophoresis. Fragments sizes
were compared to calculated fragments expected for correctly inserted cDNA fragments (Figure
3.2). PCR amplification of recombinant plasmids from transformed bacteria using EpCAM
primers indicated the presence of a 941 bp EpCAM sequence.

Figure 3. 2 Agarose gel electrophoresis of restriction enzyme digests of the three recombinant
plasmids produced for rEpCAM expression. Given below the image are the calculated fragment
sizes expected for each restriction enzyme digestion.
The TOPO TA cloning system was selected for cloning EpCAM cDNA due to the ease of
cloning and the unidirectional TA cloning property of this technique, which prevented anti-sense
orientation of the cDNA into the plasmid. Also, the technique allowed cloning of PCR amplified
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cDNA without prior purification of the cDNA from the PCR mixture, thus reducing the number
of steps involved in the cloning process while still providing high cloning efficiency. The
pEF6/V5-His TOPO plasmid also iattached carboxy-terminus (C-terminus) hexahistidine and V5
epitope tags on the recombinant protein, thus enabling purification of the protein by immobilized
metal affinity chromatography and western blot detection of the recombinant protein using antihistidine antibody or anti-V5 antibody. This property was exploited during transfer of the target
cDNa into other plasmids.
Fifteen colonies of pEF6/V5-His TOPO/EpCAM (TOPO/EpCAM) transformed E. coli
bacteria were positive for EpCAM when analyzed by PCR.

Four colonies were selected,

cultured and the recombinant plasmids purified and subjected to restriction endonuclease
digestion using BamH1 and Mlu1 enzymes (see Figure 3.2). Each enzyme produced three
fragments analyzed by agarose gel electrophoresis, the sizes of which were compared and
corresponded to the calculated fragment sized expected for a correctly inserted EpCAM cDNA.
The pcDNA 3.1 (+) vector was selected for episomal expression studies based on its
restriction enzyme map in order to allow transfer of the recombinant EpCAM-V5-His6
B

B

(rEpCAM) cDNA from the TOPO/EpCAM plasmid. The plasmid contains a SV40 gene for
episomal expression in cells expressing the SV40 large T antigen. The pTriEx-4 Neo vector was
created for expression of target proteins in multiple systems including bacteria, insects and
mammalian systems and was selected for bacterial expression of the rEpCAM protein.
To ensure unidirectional orientation of the histidine and V5 tagged rEpCAM cDNA sub-cloned
into pcDNA 3.1 (+) and pTriEx-4 Neo vectors, restriction maps of the vectors and EpCAM
cDNA were compared and restriction endonuclease enzymes selected to generate an overhang
and a blunt end each on the insert and vectors. Thus, using Kpn1 and Pme1 on the TOPO
recombinant and Kpn1 and EcoR V on pcDNA 3.1 (+), ligation of the excised histidine-tagged
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EpCAM cDNA insert into

the pcDNA episomal vector was carried out to generate the

pcDNA/EpCAM-V5-His6 recombinant plasmid. This procedure was repeated for the pTriEx 4
B
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neo vector used for bacterial expression of recombinant EpCAM. The pcDNA/EpCAM-V5-His6
B
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plasmid was restriction enzyme double digested with Xho I and Pme I to obtain the histidinetagged rEpCAM and ligated into pTriex 4 Neo treated with Xho I and EcoR V. The resulting
recombinant vectors showed correct orientation of the insert as determined by restriction enzyme
digestion (see Figure 3.2). To further confirm orientation without mutations the plasmids were
sequenced with T7, BGH and EpCAM primers and compared to the GenBank sequence for
EpCAM using the blast software. The sequence was at least 99% homologous to the EpCAM
sequence and had no mutations. Thus, large-scale plasmid amplification and purification were
carried out for mammalian cell transfection and transformation of bacteria Tuner cells for
expression studies. Based on the DNA sequence for the recombinant, the molecular weight of
the unglycosylated recombinant protein was determined to be approximately 37.033 kD.
3.3.2 Bacterial Expression Studies
Bacteria cells, Novagen Tuner(DE3)pLacI cells (EMD Bioscience,Inc., La Jolla, CA)
transformed with pTriEx 4 Neo/EpCAM plasmid were cultured overnight and sub-cultured for 3
hr at 37 °C prior to induction with various IPTG concentrations. Induced cells were incubated at
37 °C for 2.5 h and cell density measurements were obtained at 600 nm absorbance. The results
of bacterial expressions studies are shown in Figures 3.3-3.5. The OD measurements of the
growth of control and pTriEx/EpCAM transformed and un-induced bacteria over time indicated
slower growth for the pTriEx/EpCAM transformed bacteria compared to the same bacteria
transformed with the control plasmid (see Figure 3.3). The recombinant plasmid transformed
Tuner cells reached logarithmic growth phase after 3 h while the control cells were more than
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half-way through the logarithmic phase at 3 h of growth with an optical density above 1.1. The
recombinant plasmid transformed cells took almost 18 h to reach stationary phase.

Figure 3. 3: Growth curves of Tuner (DE3)pLac bacteria transformed with pTriEx 4 Neo/
EpCAM-V5-His6 and a control plasmid. The graphs show the rate of growth of the un-induced
bacteria from initial media inoculation through the stationary phase.
The slower growth rate is an indication of inhibited growth due to the recombinant plasmid. The
OD measurements of cells induced with different IPTG concentrations showed a decrease in
intensity with increasing IPTG concentration after 2.5 h of induction (see Figure 3.4). At lower
IPTG concentrations of 2.5 and 10 μM cell growth occurred at almost the same rate as for uninduced cells cultured for the same time frame.
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Above 100 μM IPTG the cell growth process was slower and at the maximum inducer
concentration of 1 mM there was no change in optical density compared to the un-induced
starting culture. In contrast however, control cells induced with 1 mM IPTG showed a slightly
higher OD after 2.5 h of induction than the 0 mM IPTG control cells incubated for the same time
period. The results thus indicate that induction of protein expression with IPTG exerted a
growth-inhibiting effect on the cells leading to under-production of the recombinant protein by
the bacteria as determined by western blot analysis.

Figure 3. 4: Optical density measurements of un-induced and IPTG induced transformed
bacteria cells, showing the effect of the recombinant pTriEx/ EpCAM plasmid on the growth of
the cells (Ep Tuner) at various IPTG concentrations. Control cells (Ctl Tuner) were induced at 0
and 1000 μM IPTG levels to determine the effect of the inducer on cell growth.
To test the effect of temperature on the ability of the recombinant colonies to produce EpCAM,
the cells were induced at IPTG concentrations of 500 μM and 1 mM and incubated at 10, 25 and
32 °C. SDS-PAGE with gelcode blue staining showed no over-expression of proteins (see
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Figure 3.5A). Results of OD measurements showed increased cell density with increasing
temperature (see Figure 3.5B), however no protein over-expression was observed for the bacteria
cultures.

Figure 3. 5: The effect of temperature on A) protein over-expression in IPTG induce cells
determined by electrophoresis with Gelcode Blue staining and B) the growth of the bacteria cells
under different temperature conditions as determined by OD measurements.
Studies have shown that some mammalian membrane proteins exert a toxic effect on the
bacterial expression hosts in addition to the lack of post translational modification mechanisms
in bacteria. Thus, these proteins cannot be produced using bacterial expression systems.32
Western blot analysis performed on the bacteria cell lysates indicated the absence of rEpCAM in
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the molecular weight range for this recombinant protein. Also, no degradation products were
detected that would indicate possible synthesis and breakdown of the protein by the bacteria.
3.3.3 Mammalian Expression of rEpCAM
Mammalian expression of rEpCAM was was next attempted using three different cell
types. BHK cells were selected for transfection studies due to the robustness of this cell type and
its widespread use in protein expression studies,7, 33 while Hep 2 cells were chosen for their
epithelial cell property to test their ability to correctly fold and post-translationally modify and
generate high yields of the rEpCAM. Cos 7 cells are used in episomal expression studies due to
the SV40 large T antigen which allows episomal vectors to induce protein generation without
genomic integration of the plasmid DNA.34

Figure 3.6 shows the results of mammalian

expression studies using these cell types. Western blots of lysates from the three cell types,
SDS-PAGE separated under non-reducing conditions and without prior heat denaturation of the
lysates, were performed with anti-EpCAM, anti-histidine and anti-V5 primary antibodies. The
anti-histidine antibody was not effective for detecting the recombinant protein and was not used
in subsequent analyses. Western blots performed with anti-V5 and anti-EpCAM antibodies
produced better results. Anti-EpCAM was more effective at detecting the native form of the
rEpCAM while the anti-V5 antibody was more appropriate for identification of the denatured
form of rEpCAM.
Western blots indicated, as expected, that for equal total protein levels of lysate the Cos7
cells produced higher EpCAM levels compared to BHK or Hep 2 cells due to episomal
expression of the protein in Cos 7 cells (see Figure 3.6). Anti-EpCAM western blots of lysate
proteins electrophoresed under non-reducing conditions showed a band for EpCAm at the
expected molecular weight of approximately 40 kD in the Hep 2 lysate and higher molecular
weight band for the Cos 7 lysates while the BHK lysate showed no EpCAM band (see Figure
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3.6A). The blots carried out using anti-V5 antibody showed multiple bands of monomeric and
multimeric forms in the Cos 7 lysates of the recombinant protein while the Hep 2 and BHK
lysates showed single bands of the monomeric recombinat protein at ~40 kD (see Figure 3.6A).

Figure 3. 6: Western blots of rEpCAM expression in three different mammalian cells. In A)
lysates from Cos 7, BHK and Hep2 cells obtained 5 days after transfection were mixed in native
sample buffer and immediately separated by SDS-PAGE on 10% tris-HCl gel prior to
electrotransfer to nitrocellulose for western blotting using antiEpCAM and anti-V5 primary
antibodies. In B and C, the lysates form stable transfectants were reduced with dithiothreitol and
heat denatured prior to SDS-PAGE separation and western blot analysis using anti-V5 antibody.
Image C also shows loss of rEpCAM expression by BHK and Hep2 cells after sub-culturing for
between 4 to 5 passages.
A western blot carried out on dithiothreitol (DTT) reduce lysates showed higher levels of the
recombinant protein in Cos 7 lysates compared to the Hep 2 and BHK lysates for the same total
protein content loaded on the gels (Figure 3.6B). Over-expression of the protein in Cos 7 cells
may have lead to formation of the observed multimeric aggregates generated in the western blots.
However, it was observed in subsequent western blots that multimeric bands observed for Cos 7
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cell were lost in transfected daughter cell culture lysates due to a progressive decline in the
protein expression levels through sub-culturing of the cells, until a steady level of monomeric
rEpCAM remained.
Prolonged production of the recombinant protein in the transfected cells at a constant
level of expression is important for the generation of adequate amounts of the protein for
downstream processes. Thus, the ability of each cell type to sustain protein production over
several weeks of culturing was determined by western blot of transfected and stabilized BHK,
Hep2 and Cos 7 cells. The transfected cells were cultured under antibiotic selection for two
weeks to produce stabilized transfectants. The cells were then split and the cultures expanded
over several passages for storage and protein production. Results indicated that production of the
recombinant protein in BHK and Hep2 cells declined and was completely inhibited after the
fourth passage of cells although the cells continued to grow in the presence of the antibiotic
(Figure 3.6C). This may be attributed to the effect of genomic integration of the recombinant
DNA on protein production leading to strict regulation of recombinant protein production by the
cells’ transcriptional and translational mechanisms.16 Thus, rEpCAM expression was down
regulated in daughter cells and with time the sequence may have been completely eliminated
from the genome of BHK and Hep2 cells. On the contrary, in transfected Cos 7 cells a steady
level of protein production was maintained up to about the eleventh passage before dropping off.
The prolonged expression of rEpCAM in Cos 7 cells compared to the BHK and Hep2
transfectants is due to the episomal expression in these cells. However, it appeared that with
time the plasmid copy numbers may have decreased in daughter cells until rEpCAM production
was solely regulated by the Cos 7 cells transcriptional and translational mechanisms leading to
loss of rEpCAM production over time. It has also been reported that BHK and Cos cells are
generally more suited for transient expression of proteins. Because of the extended expression
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time obtained with Cos7 cells transfected with pcDNA/EpCAM, this cell line was selected for
production and purification of our recombinant protein.
3.3.4 Extraction and Affinity Purification of rEpCAM from Mammalian Cells
In order to maximize protein solubilization in non-denaturing detergent various
detergents were tested for their ability to effectively solubilize proteins in the cells by comparing
the total protein contents of supernatant and pellet fractions of lysed recombinant cells. The
percentage of total protein obtained for the supernatant fractions solubilized using four mild
detergents were compared to SDS lysed cells (see Table 3.1).
Table 3.1: The mammalian cell solubilizing effiency of four mild detergents in comparison to
SDS in terms of total protein content of lysate produced used in mammalian cell lysis.

NP40 had the highest percentage of supernatant total protein content (95.5%) of the four mild
detergents with DOC having the lowest percentage of 81%. NP-40 was therefore the detergent
of choice for cell lysis.
Utilizing a lysis buffer of Nonidet P40 detergent in Tris buffered saline (TBS-NP) with
sodium molybdate, transfected Cos 7 cells were easily solubilized and subsequently centrifuged
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to remove solid material. The supernatants obtained were analyzed by western blot analysis for
rEpCAM and used in the protein purification studies. Affinity purification of solubilized
rEpCAM from Cos 7 cells was accomplished using cobalt chelated resin. The incubation time
and buffer composition were parameters optimized to selectively remove non-specifically
adsorbed proteins while retaining the bound rEpCAM.

Initial studies were carried out to

determine the incubation time required for complete binding of the protein to the resin.
Following the manufacturer’s protocol for affinity binding of histidine tagged proteins to the
Talon resin, clarified lysate was incubated with one fifth its volume of resin and incubated at
room temperature for 2 h or overnight at 4 °C prior to washing with NP-40 buffer containing
different imidazole concentrations. Results obtained indicated that longer incubation times at
4 °C were required to efficiently bind rEpCAM to the resin. At shorter incubation times up to 2
h approximately 93% of the rEpCAM was found in the unbound fraction. The longer incubation
time requirement for protein binding may be a result of the hexahistidine tag being less
accessible requiring a longer contact time for proteins to interact with the affinity resin. This,
observation was based on western blot results of lysate and purified protein fractions detected
using both anti-EpCAM and anti V5 monoclonal antibodies. It was observed in our studies that
the anti-EpCAM antibody was more effective at detecting native rEpCAM in the lysate
compared to the affinity purified protein while the anti-V5 antibody was more effective at
detecting the affinity purified, denatured and reduced forms of the protein. This indicated that in
the denatured and slightly unfolded state the V5 epitope tag was more accessible for binding to
its antibody. Also as mentioned earlier in the protein expression section of this paper, western
blots carried out on undenatured lysates using antibodies against EpCAM, V5 and C-terminus
hexahistidine tag showed no rEpCAM band using the anti-histidine antibody probably due to
inaccessibility of the histidine tag. Native EpCAM has been proposed to exist in epithelial cell
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membranes with adjacent molecules interacting laterally through the EGF2-like domain of the
protein molecules.35, 36 By expressing the bulk of the protein, the ability of the recombinant
molecules to associate in this manner may to some extent have caused shielding of the
hexahistidine tags, necessitating a longer incubation time with the IMAC resin in order to induce
binding. Western blot results also showed that low levels of the protein were left in the unbound
fraction even after overnight incubation of lysate with the resin although the loading capacity of
the resin was not exceeded in the experiments (see Figure 3.7). Thus, purification steps were
optimized to ensure optimum protein binding and maintenance of native structure of the protein.
Buffer components play an important role during affinity purification of proteins. While some
additives such as Tris can compete with the histidine tag for binding spots on the resin, other
components such as detergents, reducing agents can denature the protein. Buffer components
such as glycerol or ethylene glycol may be added to stabilize protein structure during the
washing and elution stages of purification. Thus, in this study we varied buffer composition in
terms of imidazole levels, addition or exclusion of BME in the wash buffer to provide the
optimum conditions for removal of non-specifically bound proteins. Figure 3.7 shows a western
blot of fractions from IMAC purification of Cos 7 lysate. Bound protein was treated with
different levels of imidazole in solubilzation buffer to wash and elute the recombinant protein.
Results indicated that at the Tris concentration of 50 mM used in the cell lysis buffer, rEpCAM
was eluted from the rein at imidazole concentrations as lo as 25 mM due to interference of tris
with the binding interaction between the cobalt and rEpCAM. Imidazole concentrations between
1 and 75 mM were tested in wash buffers to remove weakly bound histidine containing proteins.
From figure 3.7 it was observed that the bulk of bound protein was removed at imidazole
concentrations below 100mM.
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Figure 3. 7: Optimization of IMAC purification protocol for batch purification of rEpCAM from
Cos 7 lysate using 0.09% NP40 in TBS. The Western blot image shows elution of rEpCAM at
imidazole concentrations as low as 25 mM.
Analysis of SDS-PAGE gels of wash, elution and resin extract fractions by gelcode blue
staining showed the presence of non-rEpCAM proteins in all the fractions indicating that the use
of imidazole to selectively remove non-specifically bound proteins was ineffective (see Figure
3.8). To test the possibility that the non-specifically bound proteins were present due to strong
interactions, such as disulphide bond formation, bound protein was treated with a 10 nM BME
wash buffer for at least 20 min prior to washing with increasing imidazole concentrations.
Results indicated that although some slight improvement was obtained with the use of BME the
rEpCAM protein could not be detected with anti-EpCAM antibodies in a western blot due to
disulfide bond reduction and unfolding of the protein. Increasing the NP-40 concentration to
above 0.25% in wash buffers also led to loss of the rEpCAM in the wash buffers (results not
shown). In subsequent experiments, reducing the Tris concentration to 25 mM in the wash and
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elution buffers and diluting the lysate to half its initial concentration to decrease tris levels led to
increased binding of rEpCAM to the resin during the overnight incubation period. At the 25 mM
Tris concentration, imidazole levels up to 25 mM could be used to wash the resin bound
rEpCAM without significant protein losses. However, gel staining of the eluted fractions still
showed the presence of other proteins at significantly higher levels than the rEpCAM protein.
Pre-concentrated eluate re-incubated with Talon resin in a second affinity purification step aimed
at removing non-specifically interacting proteins resulted in re-binding of all proteins present in
the starting fraction to the resin (see Figure 3.8). This indicated that the non-rEpCAM protein
present in the eluate fractions contained surface exposed histidine clusters capable of very strong
interactions with the IMAC resin. These protein contaminants were unfortunately expressed at
much high levels compared to the target protein. Although the Talon resin was designed to
selectively bind oligohistidine-tagged recombinants for one step purification of the desired
protein, our recombinant proved to be difficult to purify in a one step process due to the
requirement for well exposed histidine tags for enhanced binding to the IMAC resin. This
finding necessitated the use of another technique in further purifying our protein target.
SDS-PAGE of lysate and purification fractions showed that after extensive washing of
the bound protein with increasing imidazole concentrations up to 25 mM prior to elution with
500 mM imidazole, the bands of proteins in the the eluate fractions were well resolved to allow
excision of the rEpCAM band without impurities.

Thus, electrophoretic separation of the

affinity purified protein could be carried out with extraction of the protein by electro elution.
With this approach 100% electrophoretic purity of the target protein can be achieved. By
combining this technique with affinity purification, the probability of co-eluting non-target
proteins with the desired protein can be greatly reduced and the purification time decreased
considerably.
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Figure 3. 8: A western blot (above) and gel images of fractions from a two-stage IMAC
purification of rEpCAM from Cos 7 lysate showing the presence of rEpCAM in addition to nonEpCAM protein contaminants present in the elution fractions. Symbols used for the fractions
collected are : L-lystae (1), U-unbound (2), w-wash (3, 4, 11, 12), E-eluates (5, 6,; 13, 14), Bresin (7, 15), S-EpCAM standard, P- positope (8), E2-ultrafiltered eluate (9), EU- unbound eluate
(10), M-markers.
In our studies, eluates of affinity purified rEpCAM were pre-concentrated and
electrophoresed on 10 % polyacrylamide gel using a 0.05% SDS Tris / glycine buffer. The gel
was stained with E-zinc reversible stain and the bands in the molecular weight range 40 to < 50
kD were excised, destained and electro eluted.

Two distinct bands were observed in this

molecular weight range and were identified by western blot as rEpCAM (see Figure 3.9) using
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both anti-EpCAM and anti-V5 primary antibodies. The two bands may be a result of different
levels of glycosylation of the protein.

Figure 3. 9: Western blots of electro elution fractions of IMAC purified rEpCAM. Western blots
were carried out with anti-EpCAM and ant-V5 primary antibodies to determine retention of
native structure of the protein.
Also the anti-EpCAM western blot results confirmed retention of native structure after the
purification process. Analysis of the band intensities for the rEpCAM protein on the western
blot images using ImageQuant version 5.2 (Molecular Dynamics Sunnyvale, CA) indicated at
least 75% recovery of the affinity purified protein after electro elution.

3.4 Conclusion
Thus, by combining a one-step IMAC procedure with electrophoresis and electro elution
a more selective approach to obtaining a target protein in highly purified form and with the
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required native conformation was achieved. With the demand for more rapid techniques for
generating biomarkers for developing analytical techniques in disease management, the ability to
integrate several biochemical processes efficiently would enable researches to achieve results in
a more timely fashion. Microfluidic devices built on polymeric platforms provide the means to
achieving this goal. The ability to incorporate several analytical processes such as the aptamer
selection process, electrophoresis and other chromatographic processes in microfluidic devices
makes it possible to combine protein target generation and purification with affinity agent
selection on a scale that allows high throughput and rapid generation of analytical reagents for
disease diagnostics without the use of large amounts of target. We have demonstrated the
production of electrophoretically pure rEpCAM in its native folded state using IMAC and
electrophoretic techniques.

Further work will involve incorporation of the technique in

microfluidic devices and coupling the process to aptamer selection to generate EpCAM specific
aptamers.
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Chapter 4 Immobilization of Aptamers onto Poly(Methyl
Methacrylate) Polymer, PMMA, Substrates for Aptamer Sandwich
Assay Development and Screening Low Levels of Protein
Biomarkers
4.1 Introduction
The analysis of protein biomarkers in biological samples is of great importance in the
area of proteomics, diagnostics and drug delivery. In many cases, a large panel of proteins must
be analyzed simultaneously in a sample that contains a large number of potential contaminants
and to complicate matters, these biomarkers must be quantified with the expression level of the
targets spanning many orders of magnitude.1

For example, tumor markers such as the

glycosylated mucin protein MUC1 over-expressed and aberrantly glycosylated on the surfaces of
cancer cells and the prostate specific antigen (PSA) are shed at low levels into the bloodstream of
adenocarcinoma patients and serves as serum biomarkers in commercial serum tumor marker
assays.2, 3
High throughput protein biomarker analysis techniques, such as immunoassays in
microtitre plate format and protein microarray technologies, in many cases provide the ability to
simultaneously screen for a large panel of these biomarkers and can produce the ability to deliver
the quantitative information required, even when the targets are present in a large excess of
interferences.1,

4, 5

Protein microarrays and biosensors utilize high affinity agents such as

antibodies, peptides or nucleic acid aptamers, which confer specificity and selectivity in target
identification without sample clean up procedures.1, 6, 7 Protein microarrays have been adapted to
the current DNA microarray technology to make use of the commercially-available array
equipment and confocal scanning systems in producing the arrays and reading their results,
respectively.4, 8, 9 Three major immunoassay formats exist for protein arrays. These are the direct
assay or reverse-phase immounoassay in which the protein of interest and the standards are
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immobilized on a platform and probed with a labeled monoclonal antibody;3,

8

the antigen

capture assay which utilizes an immobilized antibody for the capture of pre-labeled antigen; and
the sandwich immunoassay which utilizes two antibodies to capture and detect the unlabeled
antigen.8 The sandwich assay is the most effective and preferred means for target analyte
identification in complex matrices due to its high sensitivity and stringency through the use of
two antibodies .10
Despite advances made in refining immunoassays for microarrays and biosensors several
problems exist which limit the application of antibody microarrays. These include antibody
cross-reactivity with cellular proteins, difficulty in the development of sets of antibodies for
different epitopes on a target, stability of the immobilized antibody and the difficulty in adapting
current protein assay techniques to microarray format.4,

8

With the advent of nucleic acid

aptamers some of these limitations may be reduced since, for example, the coupling chemistries
utilized in DNA microarrays are applicable to aptamers and it has been reported that aptamers
exhibit less cross reactivity compared to antibodies.1
Aptamers are short single stranded oligonucleotide affinity elements which bind with
high specificity and selectivity to their targets. They are generated for analytes of interest
through systematic evolution of ligands by exponential enrichment (SELEX).11 Aptamer targets
range in size from as small as 100 daltons to very large targets such as cells.12-14 In addition,
aptamers are capable of binding target molecules with specificity comparable to monoclonal
antibodies through an induced-fit binding mechanism.15 Production methods for aptamers via
solid phase synthesis make them relatively simple to produce compared to antibodies. They are
chemically stable, less susceptible to irreversible denaturation, easily chemically modified and
can thus be readily immobilized onto a variety of functional supports without affecting their
recognition function.16 Their smaller size compared to antibodies provides a better chance of
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generating aptamers to different epitopes on a protein target and also increasing the surface
packing density of arrays and biosensors for increased assay sensitivity.16, 17
The use of aptamers in protein array and biosensor development has been studied by
various researchers using fluorescence or electrochemical detection methods for target
identification by direct target labeling or sandwich assay. In these studies glass, silicon or
polymeric substrates were employed as aptamer immobilization platforms.18-20 For example, in a
study by Collet et al (2005), functional RNA microarrays were developed on commercially
available streptavidin coated microarray slides using an automated arrayer for spotting and a
commercial microarray scanner for the readout. Test analytes were pre-labeled with fluorescent
dye for their detection.7 In separate studies by the same authors, conditions were optimized for
the production of aptamer microarrays in an attempt to determine the most suitable buffer and
pH to use for simultaneous analysis of different protein biomarkers in a given sample.19, 21 In
their studies aptamers selected under different buffer conditions during SELEX were
immobilized on glass substrate via streptavidin-biotin interaction and assayed using various
buffers and at different pHs to create optimum conditions for simultaneously identifying
different pre-labeled protein biomarkers.
Sandwich assays using immobilized aptamers and labeled antibodies were developed for
optical detection of biomarkers.2, 22 Ferreira et al (2008) developed a sandwich enzyme-linked
immunosorbent assay (ELISA) using a biotinylated aptamer and monoclonal antibody for the
detection of mucin protein, MUC1.2 In a separate study by Kirby et al., streptavidin-agarose
bead with immobilized aptamers were used for the detection of protein targets using an
electronic tongue sensor array.22 The sandwich assay format was demonstrated using anti-ricin
aptamer as capture element and a fluorophore labeled antibody for detection of the target.
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Although dual-aptamer sandwich assays have been demonstrated with electrochemical
detection using enzymatic signal amplification, no reports are available on the direct
fluorescence detection of target proteins using the sandwich assay method. Electrochemical
detection of enzymatic signal amplification for biosensors based on aptamer sandwich assays
was demonstrated in a study by Ikebukuro et al.23 In this study the authors developed an
electrochemical biosensor for thrombin using a glucose dehydrogenase (GDH) linked aptamer
sandwich-type assay. A GDH-labeled anti-thrombin aptamer was used in conjunction with a
thiolated capture aptamer immobilized on gold substrate in detecting the protein. The
electrochemical signal was generated by the action of the GDH enzyme on its quinone
substrate.23
An important contributor to performance of nucleic acid arrays and biosensors in terms of
reproducibility, probe density and availability is the immobilization of the capture element.24
Various immobilization chemistries are available for aptamer attachment on different substrates
in biosensor and microarray development. These include covalent, cross-linking and noncovalent binding interactions such as affinity binding, adsorption and absorption.4, 20, 25 One of
the most widely used non covalent immobilization chemistries is the streptavidin-biotin
interaction due to the high affinity of the biotin molecule for streptavidin.24 Covalent attachment
is the most common commercial method of nucleic acid immobilization on many supports due to
its simplicity, higher packing density and the ease of derivatizing nucleic acids during synthesis
depending on the immobilization surface and covalent linkage employed.24, 26, 27
To provide flexibility and enhance binding interaction between the capture element and
the target, long linkers can be incorporated at the end of the capture element to reduce steric
hindrance after immobilization.17 Our group recently reported on the effect of linker length on
the binding specificity of a thiol-terminated aptamer immobilized on gold slides to its target,
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thrombin, in studies using Surface Plasmon Resonance. Results indicated that by utilizing a
polyethylene glycol linker, a 4-fold increase in the binding capacity of the self-assembled
monolayer created was achieved compared to the aptamer monolayer without the polyethylene
glycol linker.28 Thus, by designing the capture aptamer with a linker to further extend it from
the surface of the support, enhanced binding interaction with the target can be achieved.
In an attempt to develop rapid, low cost, disposable single use components in diagnostic
bioassays, plastic substrates are providing a viable alternative to glass-based supports. Several
thermoplastic polymers have been used to fabricate bioanalytical devices including polystyrene,
polycarbonate 29 and poly(methyl methacrylate), PMMA, all employing different immobilization
chemistries.20 Many polymers have good optical clarity for reading microarrays via optical
techniques, with evolving chemical modification procedures appropriate for ligand attachment.24
In addition, these materials are easily molded for generating complex microfluidic architectures
in the development of integrated microdevices.30 In our laboratory, PMMA and PC have been
used for a variety of different devices and applications, including those that require
immobilization of probes, such as oligonucleotides, for DNA microarray applications.31, 32
Immobilization of nucleic acid ligands onto PMMA and PC surfaces has been achieved
through ultraviolet

33

radiation activation of the polymers to generate carboxylic acid groups as

scaffolds for carbodiimide coupling of anime terminated oligonucleotides to the polymer surface.
Studies have been carried out to determine the optimum UV exposure time for polymer
activation in order to generate a high density of functional groups and to determine which
polymer provided the best signal-to-noise ratio (SNR) for optical readout and surface loading of
the recognition element.31 These studies found PMMA to be particularly attractive for DNA
microarray studies compared to PC due to its superior optical properties and also, it showed
significantly lower levels of non-specific adsorption of targets.31 In another study by Fixe et al, a
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one-step immobilization of aminated and thiolated DNA molecules onto unmodified methyl
esters of PMMA was carried out.20 Results showed immobilized probe densities greater or
equivalent to those obtained by commercially available immobilization methods.
The focus of this study was to develop dual-aptamer sandwich assays on PMMA
substrates using direct fluorescence detection without signal amplification techniques. As a
model for these investigations, thrombin and PDGF-BB were used, because these proteins serve
as biomarkers of different diseases and are present in serum. Thrombin has been widely studied
for aptamer production and has two DNA aptamers that recognize different epitopes on the
protein.34 PDGF exists as a dimeric protein with three isoforms, PDGF-AA, PDGF-BB and
PDGF-AB. An aptamer developed toward PDGF has high affinity for the B chain of the
protein.35 Using thrombin and its aptamers we first determined the most suitable aptamer for
immobilization onto the PMMA substrate with subsequent capture of the target by considering
the ease of G-quartet structure formation of the PMMA immobilized aptamer and also the effects
of heat treatment on the adoption of the G-quartet structure. Dual-aptamer sandwich assays were
then performed using a fluorophore-labeled aptamer for direct detection of thrombin. Conditions
were optimized for a one-step covalent attachment of aptamers to UV-modified PMMA by
carbodiimide coupling chemistry, to ensure optimal aptamer density and uniformity in
immobilization for more efficient and enhanced target binding to the PMMA chip. Sandwich
assays were developed for thrombin and PDGF-BB protein using different aptamers for thrombin
and the same aptamer for PDGF protein with minimal assay performance steps and shorter assay
time.

4.2 Experimental
4.2.1 Reagents and Materials
Aptamers used in this study were obtained from Integrated DNA Technologies
(Coralville,IA)

and

are

shown

in

Table 4.1.
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Nuclease-free

water, 1-ethyl-3-(3-

dimethylaminopropyl) carbodiimide hydrochloride (EDC), N-hydroxy succinamide (NHS),
Tris(hydroxyamino) methane (Tris), 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid
(HEPES), 2-(N-morpholino)- ethanesulfonic acid (MES), sodium chloride (NaCl), magnesium
chloride (MgCl2) and potassium chloride (KCl) were obtained from Sigma-Aldrich ( St. Louis,
MO). PMMA sheets of 0.5 mm thickness were purchased from GoodFellow (Berwyn, PA), Nmethyl mesoporphyrin IX (NMM) was obtained from Frontier scientific (Logan, UT), Thrombin
was purchased from Haematologic Technologies (Essex Junction, VT) and PDGF-BB and AB
from R&D Systems (Minneapolis, MN).
4.2.2 Methylmesoporphyrin IX (NMM) Fluorescence Enhancement Test G-Quartet Structure
Formation of Immobilized Thrombin Aptamers
PMMA sheets of 0.5 mm thickness were UV activated for 15 min (wavelength 260-300
nm) and then treated with 10 μg/ mL each of the thrombin aptamers, HD1 (sequence B1) and
HD22 (sequence A) given in Table 4.1, in PBS buffer (pH 7.4) containing 40 mM NHS and 50
mM EDC for 4 h at room. The aptamer modified chips were rinsed with nuclease-free water and
stored at 4 °C overnight. To determine the conformation adopted by the immobilized thrombin
aptamers in solution, the NMM fluorescence enhancement test was performed.36 Absorbance
measurements were carried out on 40 μM NMM in Tris buffered saline (TBS) and phosphate
buffered saline (PBS) to determine the appropriate excitation wavelength using an Ultrospec
4000 UV/visible spectrophotometer (Pharmacia Biotech, Cambridge, England). One centimeter
wide strips of thrombin aptamer modified PMMA were either dipped in TBS containing 1 mM
MgCl2 and 5 mM KCl at room temperature, or dipped in the buffer at 80 °C and allowed to cool
to room temperature. Each PMMA strip was transferred to a 1 μM solution of NMM in a
fluorescence cuvette and aligned against one wall of the cuvette perpendicular to the
fluorescence emission collection path. Fluorescence measurements were obtained on a Fluorolog
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fluorimeter (Yvon Jobin Inc., Edison, NJ) between 550 and 750 nm at an excitation wavelength
of 400 nm. UV-modified PMMA strips without immobilized aptamers served as control chips.
Table 4. 1: Sequences of DNA aptamers of thrombin (A-D), PDGF (E and F) used in sandwich
assay development and the aptamer (G), a DNA variant of the prostate specific antigen aptamer,
used for optimizing the EDC/NHS immobilization protocol on PMMA. Abbreviations used in
the table are: AmMC6 = primary amine modification with a six carbon linker, iSp9 and iSp18
represent the internal spacers triethylene glycol and hexaethylene glycol respectively. The
internal spacer, iSp18, was used to further extend immobilized aptamers from the surface to
reduce steric effects and improve interaction of the aptamers with their targets.

4.2.3 Aptamer Sandwich Assay for Thrombin by Laser Scanning Confocal Microscopy (LSCM)
PMMA sheets of 0.5 mm thickness were activated by UV light (260-300 nm for 15
minutes) through a 750 mesh Nickel TEM grid (SPI Supplies, west Chester ,PA) to generate a
grid network of 25 μm2 areas of activated surface separated by 8.6 μm wide unmodified regions
that were not exposed to UV light. The UV-modified PMMA sheets were cleaned by sonication
in MilliQ water for 2 min and air dried. A 1.18 μM concentration (~ 10 μg/ mL) of aptamer A
(see Table 4.1), was immobilized on the UV modified PMMA sheets by carbodiimide coupling
chemistry using 40 mM NHS and 50 mM EDC in phosphate buffer (pH 7.4). The reaction was
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allowed to proceed for 4hr at room temperature and the HD22 immobilized chips were rinsed
with deionized water and stored at -20 °C until required for further use.
Sandwich assays were performed in PBS buffer containing 10 mM KCl, 140 mM NaCl
and 1 mM each MgCl2 and CaCl2. A 2.5 μM fixed concentration of aptamer B2 (table 1) was
incubated for 10 min with various concentrations of thrombin ranging from 0 – 1 μM at room
temperature. Twenty-five microliter aliquots of each HD1-thrombin sample was evenly
distributed onto 1” x 0.2” chips of HD22-immobilized PMMA and the assays incubated
overnight at 4 °C. The chips were then rinsed with PBS and deionized water and dried. Ten
milligrams per milliliter BSA were similarly incubated with 2.5 μM aptamer B2 and an HD22
chip and prepared for analysis. The assay chips were mounted on microscope slides with cover
slips prior to LSCM analysis.
The slides were imaged using a Leica TCS SP2 Spectral Confocal and Multiphoton
Microscope (Leica Microsystems, Mannheim, Germany) equipped with a photomultiplier tube
(PMT) detector. Images of the chips were obtained using a 63x oil immersion objective at 633
nm excitation, a scan rate of 200 Hz and the PMT set at 700 V. Images were analyzed using
Image Quant V.5 software (Molecular Dynamics, Sunnyvale, CA).
4.2.4 Sandwich Assays for Thrombin and PDGF-BB Analyzed Using a Home-Built Near-IR
Array Scanner
To generate dual aptamer sandwich assays for simultaneous detection of different
concentrations of thrombin or PDGF-BB on a single chip, approximately 1 μM of aptamer C
(for theombin capture) and E (for PDGF-BB capture (see Table 4.1) were each immobilized
onto UV-activated PMMA using 40 mM NHS and 50 mM EDC in MES (pH 6.7) buffer
overnight. The lower pH was selected to ensure protonation of the carboxylic acid groups on the
PMMA surface for enhanced formation of succinimidyl esters during the coupling reaction.
Also, a polyethylene glycol linker was introduced at the 5’ end of the aptamers to increase
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flexibility and reduce steric effects due to immobilization. The aptamer-modified chip was
dipped in TBS-TPG buffer at 40 °C and cooled to room temperature. The chip was treated with 1
μL volumes of different concentrations of protein pre-incubated with 3 μM detection aptamer
(see Table 4.1) in TBS-TPG for 5 min at 37 °C. The assays were incubated overnight at 4 °C,
gently rinsed in buffer to remove unbound protein, dried and fixed on a microscope slide with a
cover slip and scanned at 680 nm excitation on a home-built near–infrared (near-IR)
fluorescence scanner that has been previously described.31 Briefly, the scanner consisted of a
670 nm 10 mW laser diode (Thorlabs, Newton ,NJ) for sample excitation, a set of optical filters
consisting of a neutral density filter (ND 0.6; Thorlabs) and a line filter (670DF20; Omega
Optical, Brattleboro, VT), a beam splitter (690 DRLP; Omega Optical, Brattleboro, VT), a 40x
high numerical aperture (NA 0.85) microscope objective (Nikon, Natick, MA) for focusing the
laser beam on the array. The fluorescence was collected through the same objective and
transmitted through a dichroic, 700 ALP longpass and 720 DF20 bandpass filters (Omega
Optical) and a pinhole to a single-photon avalanche detector (SPAD). Samples were mounted on
an X/Y translational stage and scanned at a 50.8 μm step-size with a 0.1 s/ pixel integration time.
Data acquisition was performed using software written in Visual Basic.
4.2.5 Optimization of Conditions for EDC/NHS Immobilization of Aptamers onto PMMA
To Optimize the EDC/NHS coupling protocol by shortening the immobilization time and
increasing the immobilized aptamer density for aptamer immobilization onto PMMA surfaces
for microarray development, aptamer G in Table 4.1 was used. Approximately 1μL volumes of
various concentrations of G (5, 10, 15, 20 and 40 μM) in 50 mM MES buffer (pH 6.7) with 2%
glycerol, 50 mM EDC and 40 mM NHS were deposited on UV-modified 0.5 mm thick PMMA
chips. One chip was incubated at 37 °C for 30 min and the other for 5 h, rinsed with deionized
water and dried.

The aptamer was similarly spotted in 50 mM HEPES buffer (pH 7.2)
88

containing 0.1% PEG 400, 2 % glycerol, 200 mM EDC and 40 mM NHS on UV activated
PMMA. Incubation of the chips at 37 °C was for 30 and 80 min in a water bath prior to rinsing
and drying. The chips were scanned at 680 nm excitation on the home-built near-IR fluorescence
scanner at a 50 μm step-size and an integration time of 0.1s per pixel.
4.2.6 Sandwich Assays for Thrombin and PDGF Using Optimized Immobilization Conditions
UV-modified PMMA chips were treated with 10 μM each of amine terminated HD22 and
PDGF aptamer (aptamers C and E in Table 4.1) in HEPES buffer with 200 mM EDC and 40 mM
NHS, by inundating PMMA chips with a capture aptamer in HEPES buffer with EDC/NHS. The
aptamer immobilized chips were treated as previously described for sandwich assays with minor
changes. Instead of an overnight incubation of the sandwich assays, the assays were incubated
for 1 h at 37 °C and processed for scanning on the near-IR scanner. Concentrations of Cy5.5HD1 and Cy5.5-PDGF aptamers were fixed at 1 μM and 500 nM respectively for detection of
thrombin and PDGF.

4.3 Results and Discussion
4.3.1 NMM Fluorescence Test for Evaluating G-Quartet Structure Formation of Immobilized
Thrombin Aptamers
Schematics of the UV modification and aptamer immobilization onto PMMA and the
NMM fluorescence enhancement processes are depicted in Figure 4.1A and 4.1B.

The

immobilized capture element in an array or biosensor plays an important role in the sensitivity of
the bioassay in terms of its ability to bind the target and its packing density.16, 17 In developing a
dual aptamer sandwich-type assay for thrombin using two aptamers that recognize different
epitopes on the protein, an important consideration was the ability of the immobilized aptamer to
maintain the necessary conformation required for binding the target protein with high affinity.
The formation of an intramolecular G-quartet structure is essential to binding of thrombin by its
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aptamers.37 Thus the ability of the immobilized thrombin aptamers to form and maintain the Gquartet structure may enhance the performance of the sandwich assay. In order to select the
more appropriate of the two aptamers for capturing thrombin in a sandwich-type assay, we
considered the stability of G-quartet structure formation in addition to a higher binding affinity.
In a capillary electrochromatographic study by Joyce and McGown (2004), the adoption
of the G-quartet structure by thrombin aptamers immobilized in a glass capillary was studied
using NMM dye fluorescence enhancement.36 This dye has been shown to selectively bind the
three dimensional G-quartet structure of single-stranded DNA leading to fluorescence
enhancement of the bound dye .38 Results of the NMM fluorescence emission measurements at
610 nm performed on PMMA immobilized HD1 and HD22 aptamer chips are shown in Figure
4.1C. The absorbance maximum of NMM in Tris buffer was determined and an excitation
wavelength of 400 nm was selected for these fluorescence measurements. Samples of PMMA
immobilized aptamer dipped in 1 μM NMM after heating to 80 °C and cooling in Tris buffered
saline (TBS) showed an increase in fluorescence intensity compared to samples place directly in
NMM solution without prior heat treatment. This is due to structural re-orientation of the heat
treated aptamers to form the intra-molecular G-quartet conformation. The HD22 aptamer showed
the highest fluorescence enhancement after heat treatment due to its higher structural stability
produced by the formation of a four nucleotide DNA duplex through its 5’ and 3’ ends.37 Even
in the unheated samples the fluorescence intensity for the HD22 chip was slightly higher than
that for the HD1 chip. The HD1c sample showed the lowest fluorescence intensity of all four
samples.
Because fluorescence enhancement of NMM occurs in the presence of the G-quartet
structure, the lower fluorescence intensities obtained for the chips not subjected to heat treatment
indicated potential DNA conformations other than the quadruplex. Thus, aptamers immobilized
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on surfaces that require a G-quartet conformation for high target recognition capabilitiy may
require heat treatment prior to performing the affinity assays to enable formation of the
quadruplex structure for specific and stable target binding. Because HD22 showed the highest
fluorescence enhancement and due to its higher binding affinity for thrombin, we selected HD22
as the capture element for the sandwich assay and used HD1 as the detection probe.

Figure 4. 1: A) Schematic of the UV-modification and EDC/NHS coupling process used in
immobilizing aptamers onto PMMA, (B) Depiction of the NMM fluorescence enhancement
assay showing intercalation of the dye to the G-quartet structure of the aptamer resulting in
fluorescence enhancement. (C) The results of the fluorescence enhancement assays for HD1 and
HD22 immobilized covalently onto PMMA chips. The aptamer chips were either heat treated at
80 °C in buffer and cooled prior to immersion in NMM solution (h) or placed in the solution
without heat treatment (c) with un-functionalized PMMA as the control. Fluorescence emission
was obtained at 610nm with excitation at 400 nm. (D) Schematic depicting the aptamer
sandwich assay performed for thrombin and PDGF proteins on a PMMA substrate with
immobilized aptamers.
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4.3.2 HD1-HD22 Sandwich Assay for Thrombin Detection
One of the potential advantages of using aptamers in detection of protein targets in arrays
is the ability to spot multiple aptamers capable of recognizing different proteins for doing spatial
multiplexing and then, reading successful molecular association events by a second aptamer that
binds to another epitope on the same target, which eliminates the need for labeling the target
with a fluorophore or other reporting entity. Because thrombin and its aptamers HD1 and HD22,
which bind to different epitopes, have been well studied, we used this system as a model for
investigating the formation of aptamer recognition arrays onto PMMA solid support.

Figure

4.1D shows a general schematic of the sandwich assay adopted for the protein targets studied
herein. Because UV-irradiation of PMMA creates a functional scaffold of carboxylic acids that
can be subsequently treated with EDC/NHS to covalently attach primary amines through amide
bond formation,30 initial studies were performed with the PMMA substrate UV-modified through
a TEM grid to create regions of HD22 aptamer functionalized PMMA and areas essentially
unmodified by UV radiation and thus, contained no immobilized aptamer.

The HD22

functionalized chips were treated with target protein and a fixed concentration of 2.5 μM Cy5HD1 and imaged by LSCM after an overnight incubation at 4 °C (see Figures 4.2 and 4.3).
Figure 4.2A shows an image of a 10 nM thrombin sandwich assay chip acquired by
LSCM showing areas of high fluorescence containing the sandwich assay and regions of low
signal intensity indicating areas free of any discernible thrombin, which would indicate that only
the UV-modified regions were able to support the covalent attachment of the recognition
aptamer. In Figure 4.2B is shown the intensity plot taken from the image shown in Figure 4.2A
in relative fluorescence units (rfu). As can be seen, the fluorescence intensity dropped to nearly 0
in those areas not exposed to the UV-radiation through the TEM grid shadow mask, indicating
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the lack of any thrombin or reporter aptamer non-specifically adsorbing to the PMMA surface,
consistent with our previous results using PMMA as supports for DNA microarrays.31

Figure 4. 2: LSCM analysis of thrombin aptamer sandwich assay on PMMA UV modified
through a TEM grid showing A) an image of HD22 functionalized chip treated with 10 nM
thrombin assayed with 2.5 μM Cy5-HD1 with the detector set at PMT voltage of 700 V and B) a
graphical representation of the chip obtained using ImageQuant analysis. The line drawn across
the image in (A) represents the sampling section obtained for the profile shown in (B). Chips
were incubated overnight at 4 °C prior to scanning.
Results of LSCM imaging of the aptamer chips showed specificity of the assay for
thrombin compared to BSA (see Figure 4.3). A comparison of the average rfu values obtained
for aptamer-functionalized areas and non-functionalized areas of each sandwich assay chip
indicated a difference in intensities of the two regions for the thrombin treated chips. However,
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no difference in intensity values was obtained for the HD22-chip treated with 10 mg/mL BSA
and the HD1-Cy5 detection aptamer.

Figure 4. 3: ImageQuant analysis of LSCM images acquired for thrombin aptamer assays
performed on PMMA that was UV-modified through a TEM grid. The bar graph shows intensity
differences of the LSCM images of HD22 functionalized and unmodified regions of the PMMA
chips generated for different thrombin concentrations, BSA and the control samples. The blank
is an HD22 immobilized chip treated with Cy5-HD1. A chip treated with 10 mg/ mL BSA was
used in testing specificity of the assay for thrombin. Images were obtained at a fixed PMT
voltage of 700 V.
Also, the average intensity for the BSA chip was lower than values obtained for thrombin treated
chips indicating specificity of the assay for thrombin. From Figure 4.3 the highest values were
obtained for 1 μM thrombin. Very little change in intensity of the assay was observed for
thrombin concentrations of 100 nM and below. This may be due to the limiting effect of the
surface coverage of immobilized aptamer on the PMMA surface. Two dimensional plots of the
images, as shown in Figure 4.2, show non-uniformity in intensity of the assay regions. This is an
indication of an increased PMMA surface roughness39,
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40

which, may affect aptamer

immobilization. Also, the use of several pieces of PMMA in generating assays for different
target concentrations introduced variability in results obtained due to differences in assay
characteristics between the PMMA chips in terms of PMMA surface topography and the amount
of aptamer immobilized on each chip.
Previous reports in our group on the amount of carboxylic acid groups generated on UVmodified PMMA show that between 0.8 to 1.3 nmoles/ cm2 ( 8 to 13 picomoles/ mm2) of the
functional group are generated for 10 to 30 min UV exposure times.40 Thus, less than optimal
immobilization conditions could affect the amount of aptamer immobilized, thereby affecting the
performance of the assay in terms of the amount of protein bound and the time required for
binding interactions between the target and immobilized aptamer to occur. In this experiment
the carbodiimide coupling reaction was performed in phosphate buffer which has been reported
to interfere with the EDC coupling of primary amines with carboxylic acid groups.41
Immobilizations were thus, carried out in MES buffer at pH 6.7 to prevent hydrolysis of EDC by
phosphate buffer components.41
In order to generate sandwich assays for the detection of various concentrations of
protein on a single chip, spots of thrombin and PDGF-BB sandwich assays were respectively
generated on HD22 and PDGF aptamer-modified PMMA substrates and analyzed using a
fluorescence scanner built in-house (see Figures 4.4A and 4.4B). Figure 4.4A shows spots of
50 % serial dilutions of each protein incubated with 3 μM Cy5.5-labeled detection aptamer on
aptamer-modified PMMA. Thrombin concentrations ranged from 0 to 4 μM while PDGF-BB
concentrations were varied from 0 to 1.85 μM. Results for the thrombin sandwich assays (see
Figure 4.4B) showed an increase in intensity of the spots with increasing thrombin concentration,
an indication of the effectiveness of the sandwich assay in detecting thrombin. The assays for
PDGF-BB were less effective compared to the thrombin assay. The plot of fluorescence intensity
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versus protein concentration for the PDGF-BB assays showed an increase in signal intensity at
the higher concentrations of 925 nM and above.

Also, the assays required an overnight

incubation for detection of the target, an indication that the immobilization conditions were still
not optimal for performing the assays.
4.3.3 Optimization of the Aptamer Immobilization Protocol
We were interested in improving the rate of target binding and assay sensitivity by
increasing the aptamer surface density through optimization of the immobilization conditions in
terms of pH and EDC reagent concentration. Variations in the carbodiimide coupling chemistry
for immobilizing DNA to UV modified PMMA surfaces exist.31, 39, 42, 43 For example, multiplestep immobilization processes has been reported in which the oxidized PMMA is first treated
with EDC/NHS in MES buffer at pH 5 to enhance modification of the carboxylic acid groups.
The amine functionalized DNA to be immobilized is then added in the same buffer to generate
microarray spots.31, 42 The probe concentrations used for the immobilization processes in these
studies ranged from 100 nM to 20 μM with incubation times from 1 h to greater than 5 h.
Reports in literature indicate that although the addition of a succinimide to EDC
stabilizes the reaction with carboxylic acid groups through the formation of a more stable
succinimidyl ester intermediate, the reaction of succinimidyl esters with primary amines occurs
more efficiently at basic pH values at which the primary amines are unprotonated.44 Thus,
immobilization of the amine terminated capture aptamer may still not be efficient at the acidic
pH values necessary for EDC modification of carboxylic acid groups and longer incubation
times may be required at the lower pH to ensure higher coupling efficiency. This may lead to
excessive drying of the reaction mixture resulting in non-uniform immobilization of the aptamers.
Non-uniformity in immobilized oligonucleotide densities have been reported as a condition that
affects sensitivity of microarrays due to variation in the functional group densities on the
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surfaces of the immobilization substrate.17 In addition, evaporation of the immobilization
mixture after spotting leads to higher probe concentration at the outer edge of the spot compared
to the center leading to non-uniform probe deposition on the support, which affects the
performance of the assay.17

Figure 4. 4: Near-IR fluorescence images of 1:1 serial dilutions of thrombin (0, 0.125, 0.25, 0.5,
1.0, 2.0 and 4 μM) and PDGF-BB (0, 0.058, 0.115, 0.231, 0.462, 0.925 and 1.85) were mixed
with 3 μM Cy5.5-labeled aptamer (aptamer D and F in table 1) and spotted on an HD22 and
PDGF-functionalized PMMA slides respectively. The slides were incubated overnight at 4 °C
prior to scanning. The scan rate was 500 μm/s over a scan area of 18 x 20 mm. In (A) thrombin
samples are represented as T1-T7 and PDGF-BB samples are represented as P1 – P6 in
increasing order of protein concentration.
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Thus, to optimize the coupling efficiency for higher aptamer density and uniformity and to
shorten the time for immobilization of aptamers to PMMA surface, an aptamer amine-terminated
at the 5’ end and Cy5.5 dye labeled at the 3’ end was used.
We first carried out immobilization studies on different dye labeled aptamer
concentrations in MES buffer at pH 6.7 as previously performed for the sandwich assays to
determine the probe density in terms of fluorescence intensity at shorter incubation times. In
another set of experiments using HEPES buffer, we increased the EDC concentration to 200 mM
to compensate for its rapid hydrolysis in the presence of amine nucleophiles41 and increased the
pH to 7.2 to create a less acidic environment for better reaction of the succinimidyl ester
intermediates with the primary amine moieties on the 5’-end of the aptamer. The amineterminated oligonucleotide was added to the buffer containing EDC and NHS and spotted on UV
activated PMMA. The incubation temperature was increased from room temperature to 37 °C
and the incubation time shortened to between 30 min to 5 h for the reaction in MES buffer and
30 min and 80 min for the HEPES buffer reaction. A 2% glycerol concentration was used in the
buffers to reduce dehydration of the reaction mixtures during the immobilization process.
Results indicated that in both buffer systems the average fluorescence intensity of the
spots obtained across the width of each spot increased with increasing aptamer concentration
especially at the higher concentrations of 20 and 40 μM (see Figure 4.5A and B). Variations in
the uniformity of the spot intensities were higher at the shorter incubation time of 30 min (Figure
4.5A). By increasing the EDC concentration and increasing the pH to 7.2, the aptamer spot
intensities increased above the values obtained in MES at the lower pH and lower EDC
concentration, due to increased reaction rate at the higher EDC concentration and stability of the
carbodiimide coupling reaction at neutral pH compared to the lower pH.45 The 80 minutes
incubation in HEPES buffer provided the highest coverage density of the oligonucleotide (see
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Figure 4.5B). Based on the results obtained immobilization of aptamers for sandwich assay
development was performed in HEPES buffer at pH 7.2 for 80 min.

Figure 4.5: A) Images of a one-step EDC/NHS coupling reaction for various concentrations of
immobilized Cy5.5 labeled aptamer (G) onto UV-modified PMMA with different incubations
times of I) 30 min and II) 5 h in pH 6.7 MES buffer and III) 30 min and IV) 80 min in pH 7.2
HEPES buffer, and B) plots of fluorescence intensity of the spots showing the effect of pH and
EDC concentration on the coverage density of the labeled aptamer. The MES buffer contained
EDC at 50 mM while in the HEPES buffer EDC concentration was increased to 200 mM with a
fixed 40 mM NHS concentration in both buffers. Imaging conditions are the same as those given
in Figure 4.4.
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4.3.4 Sandwich Assay Development Using Optimized EDC/NHS Immobilization Conditions
In order to further reduce the sandwich assay time, we investigated the effects of
incubation time on the fluorescence response. Capture aptamers were immobilized at 10 μM
concentrations in pH 7.2 HEPES buffer containing 200 mM EDC and 40 mM NHS for 80 min at
37 °C. Results of the sandwich assays performed using 1 μM aptamer D for thrombin and 0.5
μM aptamer F for PDGF-BB detection are displayed in Figure 4.6.
Plots of sandwich assay fluorescence intensity versus protein concentration showed a general
increase in intensity with increasing protein concentration. The slope of the curve for the PDGF
assay (4.81 cnts/ nM) was sharper compared to that of the thrombin assay (1.42 cnts/ nM) within
the linear region of each plot (see Figure 4.6 A and B). This implied higher sensitivity of the
PDGF assay (see Figure 4.6A) as a result of the lower KD value of the PDGF aptamer. The
reported KD value for the PDGF aptamer is 10-10, whereas that for HD1 is between 10-8 and 4 x
10-7, and 5 x 10-10 for HD22.35, 37 Above a PDGF-BB concentration of 250 nM corresponding to
an aptamer to protein ratio of 2:1 and below a PDGF concentration of 62.5 nM (4:1 aptamer to
protein ratio), the fluorescence signal was no longer linear. This may be attributed to more
aptamer binding sites being available on the homodimeric protein than there are detection
aptamers at greater than 250 nM PDGF-BB concentration leading to lower fluorescence intensity
at the 500 nM concentration. At 62.5 nM concentration of PDGF-BB and below the amount of
available protein may have been so low as to cause competition between the capture and
detection aptamers for the PDGF-BB target, since the same aptamer is used in the capture and
detection of the protein. Thus, this limited the linear range of detection to less than an order of
magnitude. This problem may be rectified in the development of dual aptamer sandwich assays
for homodimeric protein targets using the same aptamer in capture and detection, through
modification of the capture aptamer.

For example, modified nucleotide bases can be
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incorporated in the capture aptamer sequence to enable covalent attachment of the protein to the
capture aptamer once bound to the chip surface.46

Figure 4.6: Sandwich assay intensity profiles of A) various PDGF-BB concentrations ranging
from 0 - 500 nM combined with 500 nM Cy5.5-PDGF aptamer and B) thrombin at
concentrations between 31 nM and 2000 nM with a fixed concentration of 1000 nM for the
Cy5.5-HD1 reporting aptamer. The assays were incubated at 37 °C for approximately 1 h before
scanning using the near-IR imager.
The use of different aptamers in the capture and detection of thrombin circumvented the
problem of competition between the capture and detection elements for the target. For the 1 h
assays performed for thrombin a linear response over one order of magnitude was achieved and
HD1-Cy5.5 could be used at an excess of 1 μM or more without affecting the assay performance
(see Figure 4.6B). Thrombin could be detected down to 31.25 nM concentration in a 1 μL sample
volume. Also it was observed that by using the optimized immobilization conditions for HD22
aptamer, the assay performance time was drastically decreased to an hour due to enhance binding
of thrombin to HD22 compared to the overnight incubations required in previous experiments in
order to detect the protein.
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4.4 Conclusion
Aptamers hold promise for the development of bioassays due to their selectivity and high
specificity. We optimized a one-step EDC/NHS coupling procedure for aptamer immobilization
onto UV-modified PMMA by using a higher pH of 7.2 and increasing the EDC concentration to
200 mM to provide increased surface density and uniform coverage of immobilized aptamers for
enhanced target binding in dual-aptamer sandwich assay development. We demonstrated the use
of thrombin aptamers in a sandwich assay with fluorescence detection without signal
amplification techniques. The thrombin sandwich assay was specific for thrombin and showed
very little interaction with BSA. Assays were performed for thrombin and PDGF-BB detection
using the optimized immobilization protocol with a resultant decrease in the assay time and with
fewer steps compared to the standard immunoassay protocols. Although an emerging class of
affinity agents, more research on improving the binding affinities of some aptamers will
eventually allow widespread use of aptamers in a variety of bioassays requiring immobilization
of aptamers. Future work will involve incorporation of aptamers in PMMA devices for capture
and detection of biomarkers or for capturing cells in disease diagnosis.
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Chapter 5 Utilization of an Aptamer Pair in Single Molecule FRET
Determination of Low Levels of Thrombin
5.1 Introduction
Some diseases are characterized by the generation of low levels of biomarkers used in
monitoring their progression and treatment effects. Hemophilia A and B, genetic disorders,
which occur due to single point mutations result in prolonged bleeding of affected individuals.1
Patients with the most common forms of this condition (hemophilia A and B) produce low levels
of coagulation factors VIII (FVIII) and IX

2

respectively.3 The mean levels of FVIII and FIX

determined for normal individuals in plasma are 0.7 nmol/L and 90 nmol/L respectively.1,

4

Individuals with the disorder produce lower levels of these factors which negatively affect
hemostasis. Various methods have been developed to detect and monitor the effects and
treatment of hemophilia. Analytical methods include, clotting time assays, enzyme linked
immunosorbent assays (ELISA) for the coagulation factors and thrombin generation tests.5-7
Thrombin, the last coagulation protease in the blood clotting cascade, exists in blood in
its zymogen form, prothrombin. When an imbalance in hemostasis occurs due, for example, to
injury thrombin generation is triggered via a cascade process requiring a host of coagulation
factors which include FVIII and FIX leading to clot formation.8 The time taken for thrombin
generation to the level required for clot formation (usually 10 nM thrombin in the initiation
phase) and the maximum level of thrombin produced during establishment of hemostatic control
(between 200-800 nM thrombin in the propagation phase) are very important parameters used in
identifying problems in hemostasis and for monitoring treatment regimes.9

In hemophilia,

thrombin generation is very slow and thus, clotting based assays can only give qualitative
information about the condition. Thus, more universal techniques for monitoring hemophilia and
treatment therapies have been developed. The thrombin generation assay, first introduced in
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1953 by MacFarlane and Biggs, is now widely used in monitoring hemophilia therapy.5, 10 This
technique measures the thrombin generation capacity of plasma by monitoring the enzymatic
activity of thrombin using chromogenic or fluorogenic peptide substrates. This allows real-time
monitoring of the thrombin generation process for detailed kinetic analysis of hemostasis.11 The
thrombin generation test allows thrombin generation in the nanomolar range to be measured
using fluorogenic substrate.12
Because of the slower process of thrombin generation in hemophilia3 a method sensitive
enough to allow direct measurement of thrombin at sub-nanomolar concentrations would allow
studies to be carried out, which could provide more insight into the effects of hemophilia
treatment options and individual variations in response to treatment regimes.

Analytical

techniques based on single molecule detection could provide solutions to problems not addressed
by the current methods for monitoring hemophilia in patients.
Fluorescence resonance energy transfer at the single molecule level (smFRET) is a
powerful spectroscopic technique for studying interactions of biomolecules at the molecular
level with advantages of being able to reveal the population distribution more directly in
heterogeneous systems and also provides the opportunity to determine the kinetics of
unsynchronized complex biochemical processes.13

smFRET can be used to detect rare

conformational transitions and for detection of transient reaction intermediates which are
difficult to detect by ensemble FRET methods. In a real-time smFRET study by Sugawa et al.,
conformational changes in the structure of immobilized Cy3-labeled H-Ras (1-171) protein
arising from binding of the protein to its substrate labeled with Cy5 dye were determined by
measuring smFRET intensity in the presence or absence of an effector capable of inducing
protein denaturation.14 Quantum-dot (QD) FRET-based nanosensors were also used in a
conformational dynamics study under capillary flow conditions to determine deformation of long
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DNA strands.15

The smFRET signal was monitored with results indicating greater FRET

efficiency observed for deformed DNA molecules under flow conditions .15 Thus, smFRET
technique provides information on the state of individual molecules which would not be
available under bulk FRET conditions.
Aptamers have emerged as a class of affinity agents capable of rivaling antibodies in
bioassay development. These molecules recognize distinct epitopes on their targets and in some
cases have affinities comparable to monoclonal antibodies.16 Their small size and ease of
generation and production make it possible to generate aptamers that recognized different
epitopes on the same target.17 Thrombin has been widely studied for aptamer selection and has
two aptamers, HD1 and HD22,18 which bind to its exosites I and II respectively making it
possible to develop assays for thrombin detection either using a single aptamer or both aptamers.
Highly sensitive aptamer-based methods for protein detection at sub-nanomolar levels have been
developed which, depend on DNA amplification for protein detection. These include the
proximity ligation assays which consist of affinity agents linked to DNA primers and a connector
DNA sequence. The DNA sequences are enzymatically ligated when in close proximity through
binding of the affinity agents to the target. The DNA is then amplified by polymerase chain
reaction for detection of the protein.19 This method was used in the detection of platelet derived
growth factor and thrombin in complex biological fluids. An affinity-based detection system
capable of detecting low levels of target without signal amplification in heterogeneous mixtures
would be an invaluable diagnostic tool for disease detection.
Heyduk and Heyduk developed a FRET-based aptamer sensor for detection of thrombin
in heterogeneous mixtures without sample manipulation.

20, 21

The aptamers HD1 and HD22

were each linked at the 3’ and 5’end respectively to one each of a complementary seven-base
long oligonucleotide sequence via five hexaethylene glycol internal spacers. The complementary
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oligonucleotide strands each had a donor or acceptor dye at the end of the short sequence
opposite to the aptamer attachment end. Co-association of the aptamer beacons with thrombin
led to enhanced annealing of the short oligo strands leading to increased FRET response. Thus,
the sensor allowed selective detection of thrombin in heterogeneous assays.20
In this study we sought to develop a smFRET-based assay for detection of low levels of
thrombin in real-time using the aptamer sensors designed by Heyduk and Heyduk. Parameters
considered included designing the complementary strand to ensure maximum FRET response
through direct attachment of the dyes to the short complementary oligomers or attachment via a
short internal linker; The ensemble FRET response of the aptamer sensor in the presence of
different concentrations of thrombin or prothrombin was also determined to ensure its selectivity
for thrombin; smFRET determinations were performed in the sub-nanomolar concentration range
to determine the ability of the sensor to detect single molecule events.

5.2 Experimental
5.2.1 Reagents and Materials
Thrombin and prothrombin used in the determinations were obtained from Haematologic
Technologies, Inc. (Essex Junction,VM). Short single stranded Cy3 or Cy5 labeled
complementary oligonucleotide sequences were synthesized by Integrated DNA Technologies
(Corallville, IA) with or without an ethylene glycol internal spacer between the dye and the
oligonucleotide strand (sequences: CGC ATC T-/Cy3/-3

and 5’/Cy5/AGA TGC G).

The

aptamer beacons designed as described by Heyduk and Heyduk (sequences: 5’/Cy5//C7/AgA
TgC g-(/hexaethylene glycol/)5-AgT CCg Tgg TAg ggC Agg TTg ggg TgA CT-3’ ; 5’ ggT Tgg
TgT ggT Tgg-(/hexaethylene glycol/)5-CgC ATC T/C6/-/Cy3/-3’) were synthesized by Midland
Certified Reagent Company, Inc. (Midland, TX). Reagents for buffer preparation including
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HPLC grade water, Tris, chlorides of sodium (NaCl), potassium (KCl) and magnesium (MgCl2)
B

B

were obtained from Sigma-Aldrich (St. Louis, MO).
5.2.2 Ensemble FRET Experiments
All bulk fluorescence measurements were carried out on a Fluorolog JY Jobin Yvon
Horiba Spectrofluorometer (Jobin Yvon Inc., Edison, NJ) and absorbance measurements of dye
labeled oligonucleotides and aptamer sensors were carried out on an Ultrospec 4000 UV/Visible
Spectrophotometer (Pharmacia biotech, Cambridge, England) to determine the excitation
wavelengths for the Cy3 and Cy5 labeled oligonucleotides.
Three prime and 5’ Cy3 and Cy5 end-labeled complementary single stranded
oligonucleotide sequences synthesized with or without an ethylene glycol internal spacer
between the dye and each sequence were diluted in nuclease-free water from which 1 μM stock
solutions in Tris saline buffer (TBS) containing 1 mM MgCl2 and 5 mM KCl at pH 7.7 were
B

B

prepared. Each oligonucleotide sequence was then combined with its complementary strand in
four different combinations depending on the presence or absence of the ethylene glycol internal
spacer to a final concentration of 250 nM each. The oligonucleotide mixtures were incubated at
37 °C for 1 h and cooled to 4 °C in a thermocycler. Fluorescence determinations on the annealed
strands were carried out at 532 nm excitation wavelength to determine the best internal spacer
combination for maximum FRET response.
For ensemble FRET measurements carried out using the aptamer sensor, samples of
thrombin and prothrombin at different concentrations ranging from 0 to 250 nM were gently
agitated at room temperature with 250 nM each of aptamer 5’-HD1-3’-Oligo7-Cy3 and Cy5oligo7-5’-HD22 in TBS (pH 8.5) containing 0.65mg/ mL polyethylene glycol, 1 mM MgCl2 and
B

B

5 mM KCl for 1 h protected from light. The solutions were excited at 532 nm wavelength and
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emission collected from 540 nm to 720 nm. The fluorescence intensity measurements obtained
near the emission maximum for Cy5 were analyzed to determine the changes in FRET intensity.
5.2.3 smFRET Analysis of Thrombin/Aptamer Complexes
For smFRET studies 1 nM samples of each aptamer beacon, a combination of the two
aptamer beacons and the beacons combined in 5 fold molar excess with thrombin were prepared
in TBS buffer (pH 8.5) with buffer components as above for ensemble FRET measurements. The
samples were incubated at room temperature with gentle shaking for 30 min and diluted to 30
pM aptamer concentration prior to analysis on a home –built single molecule detection system.
5.2.4 Instrumentation for smFRET Determinations
smFRET measurements were performed using a home-built epi-illumination fluorescence
system with two detectors as depicted in Figure 5.1. The excitation source consisted of a 10 mW,
532 nm laser diode (model: GTEC-500-532-10, Lasiris, Inc., Quebec, Canada). The laser was
directed via a dichroic mirror (Z532/780/RPC, Chroma Technologies, San Diego, CA) through a
40x, 0.75 NA focusing objective (Plan fluor, Nikon, Melville, NY) to a 5 μm spot size in a 50
μm internal diameter fused silica capillary (Polymicro technologies, Phoenix, AZ) through
which the sample flowed at 4.2 cm/s linear velocity. The capillary was mounted on an XYZ
translational stage. Greater than 90% of the fluorescence signal generated by Cy5 in the sample
and collected by the same objective, was transmitted through the dichroic mirror to a second
dichroic mirror (640DCSPXR, Chroma Technologies, San Diego, CA) which directed the Cy5
fluorescence emission through longpass and bandpass filters (FEL650/FB670-10 for Cy 5,
Thorlabs, Newton, NJ). The beam was focused by a 20x objective onto the active area (175 μm)
of a single-photon counting avalanche diode detector (SPCM-AQR-14, EG &G, Vandreuil,
Canada). Photon counts were processed by a PCI-6602 data acquisition board (National
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Instruments, Austin, TX) with a temporal resolution of 12.5 ns and analyzed using a custommade Labview v.7 software (Dr. L. Davis, UT Space Institute, TN).

Figure 5.1: Diagram of the smFRET instrument set-up showing a 532 laser for excitation of the
fluorophores and a system of dichroic mirrors and filters, and an avalanche diode detector for
detection Cy5 fluorescence emission.
5.2.5 smFRET data analysis
To characterize the transit time and demonstrate the presence of non-random correlated
single photon bursts, autocorrelation analysis was carried out using the Labview software over a
data set of 50 s. To distinguish single-molecule events from the background the Microcal Origin
software was used in determining the frequency of events and for setting a threshold for the
background photons above which single molecule photon counts represented the occurrence of
FRET.
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5.3 Results
5.3.1 Effects of an Ethylene Glycol Spacer on the FRET Response of Annealed Cy3 and Cy5
Labeled Complementary Oligonucleotide
Results of the studies to determine the length of linker for maximum FRET response are
shown in Figure 5.2. The aim of this research was to utilize the aptamer beacon under single
molecule conditions. In this regard, factors that enhance FRET intensity, such as the distance
between the dye molecules in the annealed strands, needed to be optimized to achieve this goal.
Thus we investigated the effect of attaching the dyes via a short flexible spacer molecule to the
complementary oligonucleotide sequences on the FRET response generated after the strands
annealed. The emission spectra obtained for the different combinations of linker versus no linker
yielded a higher FRET response for the oligonucleotide pair containing an ethylene glycol linker
between each oligonucleotide sequence and the attached dye. Combinations of one linker and no
linker or no linkers used produced relatively equal FRET responses for the annealed strands.
Based on the information provided by Integrated DNA Technologies concerning the dyes used,
the dye labeled oligonucleotide sequences were produced using Cy3 and Cy5 dyes synthesized
with a three carbon linker for conjugation purposes. By introducing an ethylene glycol spacer
molecule the effective linker length was increased further by 3 atoms. Thus, the results indicated
that for maximum FRET to be generated by the oligonucleotide sequence used in this experiment
a linker of approximately 6 atoms in length is required. This was taken into consideration in
synthesizing the aptamer beacons.
5.3.2 Ensemble FRET Assays of the Aptamer Beacons for Analysis of Thrombin and
Prothrombin
To determine the effectiveness of the aptamer beacons at selectively measuring thrombin in
solution, samples of different thrombin or prothrombin concentrations were prepared and mixed
with a fixed concentration of the two aptamers. Figure 5.3 shows results of variation of FRET
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response with protein concentration. At 250 nM aptamer concentration an increase in FRET
response was observed for thrombin from above 25 nM protein.

Figure 5.2: FRET and fluorescence emission spectra for annealed complementary sevenoligonucleotide sequences and the Cy5-labeled sequences in TBS buffer at pH 7.7. Excitation
was carried out at 532 nM and the fluorescence emission spectra obtained for Cy5 emission.
Both oligonucleotide sequences were synthesized with the FRET dyes attached with (represented
by a prime (‘)) or without an ethylene glycol internal spacer between the dye and the sequence to
determine the best linker combination for maximum FRET response.
No variation in FRET response was observed for prothrombin indicating specificity of the
technique for thrombin. The assay required association of both aptamers with the protein
molecule in order to enhance annealing of the signaling complementary oligonucleotide strands.
Since exosite II is unavailable in prothrombin the co-association process was hindered leaving
the FRET response unchanged in the presence of prothrombin.22 We were thus able to ascertain
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proper functioning of the aptamer beacons for subsequent experiments at the single molecule
level.

Figure 5.3: Variation in ensemble FRET response for aptamer beacon assays with increasing
concentration of thrombin or prothrombin in TBS at pH 8.5. The HD1 and HD22 beacon
concentrations were fixed at 250 nM.
5.3.3 smFRET Analysis of Thrombin-Aptamer Assays
The FRET beacons were used in single molecule studies for detection of picomolar levels
of thrombin in solution. The home-built system was initially optimized for single molecule
detection using fluorescent beads. To obtain the probe volume and concentration for probability
of single molecule occupancy, the beam waist was determined experimentally at different sample
flow rates using an autocorrelation function built into the Labview software. The beam diameter
was determined to be 4 μm and used to estimate a probe volume between 133 and 222 fL. Based
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on the results, the concentration of analyte required for single molecule occupancy of the probe
volume was determined to be 6 pM at a sample linear velocity of 4.244 cm/s.
Pre-incubated samples of the aptamer beacons were analyzed after dilution to picomolar
concentrations and the fluorescence generated by Cy5 was monitored for smFRET occurrence.
Results of the smFRET analysis are shown in figures 5.4 and 5.5. Figure 5.4 shows photon burst
data collected over 50 s time intervals for buffer, 30 pM Cy5-HD22, a mixture of the two
aptamer beacons at 30 pM concentrations and both aptamers pre-incubated with thrombin in a 5
fold excess aptamer to thrombin ratio. The amplitude of photon bursts for the buffer and
aptamer samples were below 4000 counts/s on the average. With the addition of thrombin to the
sample the amplitude of photon bursts increased above 105 counts/s. To eliminate false positives
P

P

due to excitation of Cy5 by the laser and formation of a FRET pair by the aptamer beacons in the
absence of thrombin, the photon counting threshold was set at 4000 counts/s (see Figure 5.5) and
the frequency of photon bursts above this threshold computed to determine the number of events
for smFRET produced for the thrombin-aptamer complex. At 6 pM thrombin and a 5 fold excess
of aptamer beacons the frequency of molecular events was 27 above the 4000 counts threshold.
The expected number of events (Nev) was calculated from the equation below.23
B

B

Nev= 2PoνT/πω
B

B

B

B

Where Po represents the probability of single molecule occupancy in the probe volume, ν is the
B

B

linear flow velocity (4.2 cm/s), T is the duration of the experiment (50 s) and ω is the laser beam
diameter (4 μm). Based on a probability of 0.01, Nev was calculated to be 3342 for the 50 s
B

B

duration, which is far higher than the experimental results obtained.
Formation of a thrombin aptamer complex is governed by binding kinetics affected by
the dissociation constant of the complex. HD22 has a higher affinity for thrombin with a
dissociation constant (KD) of 0.5 nM while that for HD1 is between 1.4 to 100 nM.18 Assuming
B

B
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the KD values remain unchanged for both aptamers during complex formation with thrombin, the
B

B

6 pM thrombin and 30 pM aptamer concentrations are well below the KD of each aptamer and
B

B

formation of the complex or retention of its structure after dilution during analysis would be
affected.

Figure 5.4: Computer generated readouts of the assays showing the rate of photon count with
time obtained on the Cy5 fluorescence detector for A) buffer only, B) 30 pM Cy5-HD22 beacon
in buffer, C) 30 pM HD1-Cy3/Cy5-HD22 mixture in buffer and D) 30 pM HD1-Cy3/Cy5-HD22
with 6 pM thrombin. Samples were prepared in buffer at pH 8.5, incubated at room temperature
at a higher concentration and diluted to 30 pM aptamer beacon concentration prior to analysis on
the smFRET system.
Thus, the lower molecular event counts obtained are a result of samples being analyzed at
concentrations below the KD of the aptamers. To enable single molecule detection of low
B

B

thrombin concentrations the probe volume can be adjusted to allow higher sample concentrations
to be used. By introducing a pinhole in front of the detector, the probe volume can be further
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decreased. Alternatively, a higher magnification objective with high numerical aperture, such as
a 100X oil immersion objective can be used to focus the beam to an even smaller diameter. By
decreasing the probe volume, concentrations of aptamer and thrombin in the nanomolar range
can be used for sample analysis.

Figure 5. 5: Plots of photon burst data obtained for smFRET analysis of the aptamer assay
showing the frequency of molecular events obtained at different count rate thresholds for Cy5HD22, both aptamer beacons without thrombin and the assay with thrombin at 6 pM
concentration

5.4 Conclusion
Aptamers have emerged as potential affinity agents that rival or complement antibodies
in developing diagnostic assays for disease detection. Single molecule detection methods also
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provide high sensitivity techniques in which aptamers can find use. We have demonstrated the
use of two aptamers in a FRET-based assay for the detection of low levels of thrombin.
Sensitivity and reliability of the smFRET assay depends on formation of the complex and its
stability. Due to the dissociation constants of the aptamers, low levels of molecular events were
detected for a 6 pM concentration of thrombin. Future work will involve adjusting the single
molecule system by eithere the use of a higher magnification lens or use of pinholes to enable
analysis of higher concentrations of samples.
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Chapter 6 Conclusions, Current and Future Developments
6.1 Conclusions
We have demonstrated the use of aptamers in analytical applications including microchip
affinity CGE, aptamer sandwich assays on PMMA substrate and smFRET analysis and
expressed and purified a membrane protein biomarker as a possible target for aptamer selection.
In the microchip CGE assay aptamers derived towards thrombin were compared to determine the
one most suited for thrombin quantification in plasma. The HD22 aptamer with a higher binding
affinity than HD1 aptamer was able to form well resolved aptamer-thrombin complexes during
microchip CGE separation. Concentrations as low as 10 nM thrombin could be detected by this
method. De-salted plasma samples diluted to 10% in running buffer were successfully analyzed
for thrombin with microchip CGE separations performed in less than one minute.
We also expressed a histidine-tagged rEpCAM in bacteria and mammalian cells to
determine the system best suited for large-scaled production of the protein. The episomal
expression method in Cos 7 cells was selected, due to higher protein yield, for production of
rEpCAM. To ensure high purity of protein in its native state a selective purification technique
based on a tandem IMAC with electro elution was developed. Using this purification method
electrophoretically pure protein was obtained and detected by western blot using an anti-EpCAM
antibody specific for the native form of EpCAM. This technique may be effective in the
purification of histidine-tagged proteins expressed in eukaryotic systems in which histidine-rich
contaminating proteins affect purity of the target protein.
Aptamers have an advantage over antibodies due to their chemical and thermal stability,
ease of chemical modification and resistance to denaturation when immobilized on surfaces. The
use of an aptamer pair in a sandwich assay format was developed on PMMA substrate using
thrombin and PDGF aptamers. To increase the capture element density and enhance target
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binding the immobilization conditions were optimize by using neutral pH and 200 mM EDC
concentration in the immobilization process. In the thrombin aptamer assay, HD22 served as the
capture element due to its higher binding affinity and ability of its immobilized form to maintain
the G-quartet structure as determined by NMM fluorescence enhancement. The HD1 aptamer
was dye labeled and served as the detection aptamer. In the PDGF-BB sandwich assay, the
aptamer served both as the capture and detection elements due to the homo-dimeric nature of the
protein. Results indicated higher sensitivity for the PDGF-BB assay compared to the thrombin
assay due to the higher binding affinity (KD=100 pM) of the PDGF aptamer. However, its linear
B

B

dynamic range was smaller due to competition between the immobilized aptamer and the
detection aptamer for the protein target. The thrombin sandwich assay had a larger dynamic
range and since both aptamers recognize different epitopes the binding kinetics was unaffected
by competition for similar binding sites on the protein.
Initial results in the development of an aptamer-based smFRET technique for detection of
low levels of thrombin indicated that aptamers can be effectively utilized for single molecule
detection of biomolecules. However, detection of the aptamer-protein complex at low picomolar
concentrations was greatly affected by the dissociation constant of the aptamers. The single
molecule detection system needs to be optimized to allow utilization of analyte and reagents at
concentrations above the KD of the aptamers.
B

B

6.2 Current Work
Detection of analytes in the single molecule realm lends sensitivity to analytical
techniques in the analysis of biomolecules. By decreasing the detection volume, background
interference is drastically reduced thus increasing the signal-to-noise ratio. In the aptamer-based
smFRET studies samples of pre-incubated aptamer beacon and thrombin were diluted to low
picomolar concentrations prior to analysis. With the lowest aptamer beacon KD value of 500 pM
B
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the concentrations required for single molecule detection were far below concentrations required
for complex stability or formation. Detection of the aptamer-thrombin complexes formed in the
aptamer smFRET assay can be achieved by maintaining the concentrations of the target and
aptamer beacons in the nanomolar range. This can be achieved by controlling the probe volume
through focusing the laser beam into a tighter spot. To achieve this, a high magnification
objective such as an oil-immersion objective with high numerical aperture (NA ~ 1.3) can be
used to increase resolution. Alternatively a pinhole can be used to decrease the probe volume to
about 1 femtoliter. With this probe volume size analytes in nanomolar concentration range can
be used for single molecule detection.
Current modifications are underway to decrease the laser beam diameter for the homebuilt single molecule system by the use of a pinhole or replacing the 40x objective with a 100x
oil-immersion objective lens. With these modifications smFRET detection of aptamer-thrombin
complexes will be easily accomplished thereby increasing the scope of analytical applications of
aptamers.

6.3 Future Developments
The need for generating more aptamers with high specificity for targets has given rise to
automation of the SELEX process and utilization of microfluidic devices for the aptamer
generation process.1,
P

2
P

A high throughput process for SELEX of protein targets involving

integrated purification and selection methods on polymeric microfluidic platform would further
enhance aptamer generation for multiple targets.

A simple microfluidic device for IMAC

purification and aptamer selection containing nanoposts functionalized with tetradenate chelating
groups for immobilizing nickel or cobalt ions can be designed for purification and
immobilization of polyhistidine tagged proteins (see Figure 6.1).
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Figure 6. 1: Diagrammatic representation of the layout of a simple polymeric microdevice for
immobilizaton and purification of histidine-tagged proteins with subsequent electrophoretic
separation of complexes formed with nucleic acid strands in a degenerate library for aptamer
selection. Reservoir A contains nanoposts functionalized with tetradentate chelating groups for
immobilized metal afinity purification in channel AB with channel CD as the separation
channel.
Histidine-tagged protein targets can be captured on the IMAC nanoposts and purified by washing
with the appropriate buffers in the purification channel (AB in Figure 6.1). The purified target is
then incubated with a random library and the washing steps performed to remove unbound target
as is performed in the SELEX process. Alternatively, the mixture of oligonucleotides and protein
target can be directly injected, after the incubation period, into the cross-section of the device
and separated in the separation channel (CD in figure 6.1) by non-equilibrium capillary
electrophoresis.3 For simultaneously processing several targets a multichannel version of the
P

P

microdevice could be designed. The microfluidic format for aptamer selection enables utilization
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of less reagent and would provide an inexpensive means of generating aptamers toward protein
targets.2
P

P
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